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Tumors are heterogeneous organ-like tissues including not only tumor cells themselves but also 
auxiliary cells such as, endothelial cells, fibroblasts, inflammatory cells, and bone marrow 
derived stem or stromal cells (BMSCs), which collectively create the surrounding 
microenvironment also referred to as stromal compartment. By now the active role of the tumor-
stroma in driving the dissemination phase and the following engraftment of tumor cells in 
secondary organs is widely accepted. Indeed, the perpetual activation of stromal cells is 
extended beyond the local primary tumors and they can take part in preparing a permissive 
environment at distant anatomic sites by providing oxygen and nutrients essential for tumor 
growth and invasion. 
Tenascin-W (TNW) is a matricellular protein with a dynamically changing pattern of expression 
during development and disease. Its pronounced presence in developing bones implies a 
function in osteogenesis. In adults, tenascin-W is mostly restricted to stem cell niches, and is 
also expressed in the microenvironment of solid cancers. These distinct expression patterns 
imply a complex regulation of tenascin-W gene expression at the transcriptional level. Here we 
analyzed tenascin-W expression in a xenograft model of breast cancer metastasis to the bone. 
Quantitative mRNA analysis revealed an upregulation of tenascin-W in mouse osteoblast 
populations sorted from bones harboring human breast cancer metastases. Long bone sections 
containing metastases exhibit expression of mouse tenascin-W protein proving that tenascin-W 
is supplied by the metastatic niche and not by the tumor cells. Transwell and co-culture studies 
show that bone marrow stem cells (BMSCs) express tenascin-W protein after exposure to 
factors secreted by MDA-MB231-1833 breast cancer cells. These findings prompted us to 
investigate the cis and trans-acting elements that drive tenascin-W                   . 5’RAC  
analysis of mRNA from human breast cancer, glioblastoma, and bone tissue showed a single 
tenascin-W transcript with a transcription start site (TSS) at a non-coding first exon upstream of 
exon2, which contains the translation start codon (ATG). The promoter region between -957bp 
and -79bp influences transcription and the minimal promoter sequence is contained within 79bp 
from the TSS. Computational analysis shows the presence of Smad4 nuclear transcription factor 
binding site at -61bp from the TSS in proximity of a TATA box sequence. Site-directed 
mutagenesis of the Smad4-binding site strongly impaired the SEAP reporter gene expression 
driven by the basal promoter. Furthermore, we found three evolutionary conserved regions in 
the first intron harboring glucocorticoid response elements (GRE), which negatively affect 
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transcription initiation from the basal promoter (-79bp). Therefore, we assessed whether TGF1 
and glucocorticoids (GCs) act on tenascin-W gene expression in the tumor context. We 
identified TGF1 as an important factor inducing human tenascin-W gene transcription in 
BMSCs through activation of ALK5. Preincubation of BMSCs with the ALK5 inhibitor, SB431542, 
abolished tenascin-W induction by TGF1. Moreover, GCs impaired tenascin-W mRNA 
expression in BMSCs. Finally, recombinant tenascin-W protein stimulated MDA-MB231-1833 
cell proliferation and migration in vitro assays. Our experiments suggest that tenascin-W acts as 
a niche component for breast cancer metastasis to the bone by supporting cell migration and 
cell proliferation of the breast cancer cells. 
The analysis of the tumor bed contribution to cancer progression is a new frontier to unravel. It 
will lead to novel approaches to interfere with mechanism implicated in drug resistance, tumor 
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II. Introduction  
Cellular pathways are controlled by a multitude of diverse intercellular communication 
processes. In multicellular organisms, the exchange of signals often depends on the 
compartment outside of cells, which provides a behavioral code to cells that interact with it. 
Indeed, different cell types such as fibroblasts, endothelial cells and immune cells within the 
tissue microenvironment are embedded in a complex meshwork of non-cellular components 
called extracellular matrix (ECM) made up from glycosaminoglycans (GAGs), collagens, 
glycoproteins, and proteoglycans (PGs). The ECM defines the fundamental spatial organization 
of the cell, contributing for instance to the apical-basal configuration of epithelial cells. Among 
several functions, the apico-basal orientation is pivotal for the asymmetric division of epithelial 
stem cells and lack of polarity contributes to the switch into symmetric divisions, resulting in 
stem cell-derived tumors (1). Cell-cell adhesion occurs through the lateral cell domain, which 
presents intercellular junctions, whereas hemidesmosomes anchor the cell to the extracellular 
matrix of the basal lamina. The latter is attached to the external, fibrillar reticular layer, together 
making up the basement membrane (BM), which includes several macromolecules such as type 
IV collagen, laminin, fibronectin, nidogen, agrin, perlecan and heparin sulfate proteoglycans (2-
4). All these ECM ligands ensure a highly controlled communication with cells through the 
interaction with cell surface receptors such as integrins, a family of heterodimeric 
transmembrane glycoproteins (5, 6). The integrins are linked to the cytoskeleton by a large 
complex of different proteins including i.e. integrin-linked kinase (ILK), an adaptor protein that 
binds the cytoplasmatic tail of integrins, allowing transduction of signals from outside into the 
cell (7). Intracellular signal transduction is coupled with actin cytoskeleton remodeling leading to 
a variety of processes that control cell shape change, gene expression, proliferation, migration, 
differentiation, and survival. In addition to the common ECM integrin-binding motif, Arg-Gly-Asp 
(RGD) present in many ECM proteins, other sites are used for tethering to other cell surface-
adhesion receptors, such as discoidin, syndecan, cadherin, Ig-CAM and selectin (8, 9). Yet 
other domains present in ECM proteins are necessary for binding growth factors. Binding sites 
for cytokines and growth factors have been found on glycosaminoglycans or small leucine-rich 
repeat proteoglycans (SLRPs) (10, 11). Additional proteoglycans, such as decorin, allow the 
access of TGF ligand to its receptor (12). A synergism has been shown between integrins and 
syndecan (13) and integrin occupation with growth factor signaling (14). For instance, receptor 
synergy between syndecan-4 and integrin is essential for the spreading of cells on fibronectin 
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(15). Different integrin receptor combinations in association with a multitude of ECM ligands can 
modulate adhesive events, thus, contributing to tissue properties during different developmental 
phases including the embryonic stage, or the inflammatory response and wound healing in adult 
tissue. Finally, the highly distinctive organization of ECM in tumors as compared to normal 
tissue reflects specific functions in disease. Therefore, it is of fundamental importance to explore 
not only the passive, space-filling contribution of ECM proteins but also their major active role in 
regulating tissue homeostasis.  
II.1 The bright side of ECM during cellular processes and tissue repair 
II. 1.1 Extracellular matrix: Platform of signal exchange with cells 
Beyond the parameters which define ECM proteins as a physical scaffolding for cells and being 
in charge of attenuating external forces, such as hydrostatic pressure or tensional stress, more 
recently a more active ECM role in different cellular processes was proposed. The coexistence 
of several domains and motifs in the ECM proteins is important for the potential interaction with 
many factors (Fig.II.1) (16).  
 
Figure II. 1: Multidomain interaction of ECM proteins with cells  
Domains present on ECM proteins, such as fibronectin (green structure) are essential for the binding of integrins such 
as RGD (*) or LDV (#) as showed for 51 and 41. Growth factor VEGF binds two receptors: heparan sulfate 
chains of syndecan (purple/blue) and VEGRF2 (yellow). Integrin 56 interacts with LAP protein, thus activating 
TGF. Through the N-terminal region of fibronectin the inactive TGF form can simultaneously interact with fibrillin. 
HGF binds the transmembrane HGF- receptor (MET, pink) and the integrin receptor linked to fibronectin (16).  
 
Furthermore, such interactions can depend on alternative splicing mechanisms occurring in 
ECM protein domains or adhesion receptors leading to the inclusion or omission of specific 
binding motifs, thus influencing the association with certain molecules. An example of this is 
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fibronectin where the aberrant inclusion of the EDA domain was linked to fibrosis and 
thrombosis (17). Other mechanisms of creating ECM protein variants with different functions are 
the incomplete processing shown for type II procollagen. Two isoforms were shown to be 
differentially expressed during formation of the endochondral skeleton, with the isoform type IIA 
retaining the N-terminal propeptide displaying the specific capability to bind TGF and BMP2, 
two factors known to regulate chondrogenesis (18, 19). Diversity is further increased by multiple 
genes encoding different protein family members. This is the case for TGF, where many cells 
secrete precursors of different TGF isoforms in a latent form, associated with LAP (latency-
associated peptide). This latent complex is in turn bound to latent binding protein (LTBP) (20). 
The cleavage of fibrillin or other ECM proteins from the LTBP complex by metalloproteases 
leads to the release and the subsequent activation of TGF. The interaction of integrin with LAP 
also leads to the activation of TGF (Fig.II.1). Sometimes juxtaposition of two receptors bound 
to the same ECM molecule is required for the activity of growth factors (Fig.II.1). For instance, 
the binding of vascular endothelial growth factor (VEGF) to the two receptors integrin 51 and 
VEGRF2 bound to the same fibronectin protein is essential in promoting endothelial cell 
proliferation and migration (21). In contrast, hepatocyte growth factor (HGF) requires the binding 
to two different ECM molecules, fibronectin and vitronectin, to exert its pro-angiogenic function 
(22). Therefore, ECM acts as a multidomain platform on which many factors converge to trigger 
a highly regulated response.  
II. 1.2 Bidirectional communication between ECM and the stem cell niche 
The hematopoietic niche in the adult bone marrow includes cells of different lineages, such as 
osteoblasts, vascular endothelial cells, neural cells and immune cells (Fig.II.2). Significant 
influences on the stem cell niche arise also from non-cellular elements, such as ECM 
components and secreted factors (23). In 1978, Schofield discovered the relevance of the 
surrounding environment in determining hematopoietic stem cell behavior (24). ECM proteins 
can act as a reservoir of growth factors (Fig.II.3). Therefore, they can influence the balance of 
stem cells between self-renewal and differentiation by modifying the biochemical composition of 
the cellular microenvironment (25). Furthermore, ECM can influence the localization of stem 
cells through cell-matrix interactions mediated by integrins (Fig.II.3) (26). In addition, mechanical 
tension can induce the release of specific factors by the ECM or the exposure of biologically 
active cryptic sites within ECM proteins following structural changes (27).  





Figure II. 2: Stem cell niche  
The stem cell niche includes structural components, such as ECM matrix and different types of cells: immune cells, 
endothelial cells and neurons. Secreted factors  are involved in the regulation of the stem cell niche fate (23).  
 
In turn, secreted factors can mediate the indirect communication between stem cells and the 
niche, thereby affecting the ECM composition. For instance, during the granulation stage in 
wound healing, various cytokines and growth factors act on the different fibroblastic cell 
subpopulations in the connective tissue. Besides local fibroblasts, this also includes 
mesenchymal stem cells (MSCs).  Fibroblasts produce a large amount of ECM proteins during 
scar formation. However, other cell sources such as myofibroblasts can further sustain matrix 
deposition. One of the main fibrogenic mediators is TGF a potent inducer of myofibroblastic 
differentiation (28). Myofibroblasts originate from either local fibroblasts through the epithelial-
mesenchymal transition (EMT) or from local stem cells (29). Therefore, secreted factors are able 
to induce significant changes within the niche thereby indirectly targeting the stem cells.  




Figure II. 3: Cross-talk between stem cell niche and ECM 
Stem cell niche includes structural components, such as ECM matrix. ECM proteins are a sink of growth factors, 
influencing stem cells behavior. ECM-integrin complex allows the anchorage of stem cells. ECM-physical properties 
contribute to changes in stem cells activity (27).  
 
II. 1.3 Epithelial-mesenchymal transition and the role of TGF  
Epithelial-mesenchymal transition (EMT) is a process which does not only affect differentiated 
adult cells but is also an important step required for the germ layer formation and the cellular 
motility and invasiveness during embryonic development (Fig.II.4) (30).  
EMT transition consists in the acquisition of mesenchymal features with a migratory phenotype. 
Many EMT factors, such as Snail or Twist, are induced by different growth factors. Especially, 
Snail is a transcription factor that represses epithelial markers such as E-cadherin and its 
transcription is induced by TGF(31). Loss of this marker is associated with the disruption of 
adherens junction. Secretion of metalloproteases helps the degradation of the basement 
membrane and the compromised ECM structure leads to the loss of cell polarity (32). The 
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recruitment of MSCs at injury sites or, in a worse scenario, at tumor sites is initiated by the EMT 
process (Fig.II.4). Therefore, since EMT promotes cell invasion and migration, it is obvious to 
imagine how frequently this cell transition plays a crucial role in the development or tissue repair 
and in the onset of metastases. 
Once that cells have migrated towards their destinations, due to their plasticity, they can revert 
back into an epithelial phenotype through a process named MET, for mesenchymal-epithelial 
transition (33).  
 
 
Figure II. 4: Epithelial-mesenchymal transition  
Acquisition of a mesenchymal phenotype occurs during embryonic development and in adult stage, at injury sites and 
in metastatic tumors (34). 
 
II. 1.4 Differential transcriptional regulation of growth factors involved in the EMT 
process 
TGF is the prototypical EMT inducer. Members of the TGF superfamily include TGF itself, 
activins and bone morphogenetic proteins (BMPs). Like many other ubiquitous growth factors, 
TGF shows versatile functions that differ according to the physiological context or the degree 
of injury. Although TGF can act as a potent inhibitor of cell proliferation (35), in a pathological 
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scenario, the loss of important components of the TGF-mediated cell cycle arrest program, 
such as c-myc in cancer cells (36) or the genetic inactivation of specific TGFreceptors (37) 
lead to the defective inhibition of cancer cell growth by TGF (38). BMPs are involved in 
regulating vascular cell proliferation and differentiation but, similarly to the dual role of TGF, 
defects in BMP signaling pathway generate hereditary vascular diseases (39). 
BMP2 and TGF signaling pathways are mediated by transmembrane serine/threonine kinase 
type I and type II receptors. TGF-1 binds to type I TGF receptor /ALK-5, whereas BMP to type 
I /Alk3. Once that type I receptors get phosphorylated by the type II receptors, Smad family 
intracellular proteins are activated. Smad2 and Smad3 mediate TGFand activin signalling, 
whereas Smad1, Smad5 and Smad8 act downstream of BMP receptors. The final common 
mediator is Smad4, which following its translocation to the nucleus regulates gene transcription 
by directly binding DNA or by interacting with other transcription factors, co-activators and co-
repressor (Fig.II.5) (40-42). Non-canonical TGF-Smad signaling pathways are mediated by 









Figure II. 5: The canonical TGF superfamily Smad signaling pathway (42) 
The importance of TGFubiquity and versatility becomes evident in the recovery from liver 
injury. Through TGF stimulation, hepatic stellate cells (HSCs) undergo a mesenchymal-
epithelial transition to transdifferentiate into liver progenitor cells to ensure liver regeneration 
following partial hepatectomy (PH) or chemical insults (43). Furthermore, TGF is also a major 
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inhibitor of hepatocyte proliferation (44). This explains why the conditioned medium collected 
from HSCs early after PH injury contains low levels of TGF, while it is enriched in hepatocyte 
growth factor (HGF) and platelet-derived growth factor (PDGF) to promote hepatocyte 
proliferation. On the contrary, during terminal phases of liver regeneration HSCs produce high 
levels of TGF(45). This transient role of TGF in sustaining EMT and hence ECM deposition is 
regulated by differential phosphorylation of specific sites within Smad proteins. More precisely, 
TGFsignaling through Smad2/Smad3 elicits cytostatic and EMT downstream signals, thus 
leading to the inhibition of HSCs proliferation and the enhancement of collagen synthesis. In 
turn, Smad7 induced by Smad3 interrupts the Smad phosphorylation cascade. In doing so, 
Smad7 induces a negative feedback mechanism in the fibrogenic activity of TGF(46). 
II. 1.5 The physiological action of ECM proteins during the inflammation process 
All sources of physiological insults such as infectious agents, tissue injuries or tumors cause a 
rearrangement of the ECM. ECM components represent the first barrier for the infiltration of 
inflammatory cells of the organism (47). During the process of extravasation, integrin-ECM 
interactions allow the adhesion of neutrophils to the vascular wall. Neutrophils constitute the first 
line of defense during infection, and contribute to the destruction of invading pathogens (48, 49). 
Importantly, removal of bacteria or oxidative burst by phagocytes is mediated by their adhesion 
to various ECM components (50). During the infection processes, Toll-like receptors (TLRs) do 
not only recognize exogenous danger signals such as bacterial lipopolysaccharide (LPS) but 
also endogenous factors (Fig.II.6). Interestingly, it has been shown that specific ECM domains, 
such as the fibrinogen-like globe of tenascin-C, are capable of inducing TLR4 activity in arthritic 
joint disease (51).  
II. 1.6 The ECM and the control of wound healing 
The hierarchical organization of fibrillar matrix arises from collagen crosslinking catalyzed by 
different enzymes, such as lysyl oxidase (LOX). This assembly of collagen molecules into fibrils 
results in a compact tissue important in preventing skin injury (10). In wound closure two 
physiological processes are essential: regeneration and tissue repair. In addition to the 
secretion of inflammatory mediators already mentioned above, several cell types participate in 
the granulation phase. Adjacent to the injury, healthy cells undergo mitosis to replace the lost 
cells. Repair of damaged tissue is provided by fibroblasts, endothelial cells and keratinocytes. 
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Fibroblasts secrete growth factors and induce new matrix deposition, which is responsible for 
the patching of harmed sites (Fig.II.6).  
 
 
Figure II. 6: ECM proteins and activation of immune cells  
Cleaved ECM proteins generate bioactive fragments which are responsible for the immune response mediated by 
Toll-like receptors. ECM deposition in tissue repair is controlled by resident fibroblasts and remodeling of the matrix is 
regulated by several metalloproteases (MMPs). Integrin-ECM axis mediates neutrophil infiltration in inflammation 
(47).    
During wound healing, in order to balance the excessive matrix deposition by fibroblasts, which 
is the main cause of fibrosis, the extracellular matrix protein CCN1 promotes fibroblast 
senescence by inducing Nox1 and subsequently leading to an increased amount of ROS (56). 
For this, CCN1 requires the association with integrin 61 and heparan sulphate proteoglycans 
(52). The deposition of ECM proteins, which occurs during fibrous scar formation, is also 
balanced through the activity of metalloproteases, which are tightly regulated by ROS in 
conditions of hypoxia following microvascular injury (53). Collagenase is an interstitial enzyme 
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expressed by keratinocytes. Its activity is important to remove the large amount of matrix 
proteins present during scar formation to allow cell migration (54). The ECM is also important for 
wound re-epithelialization. Keratinocyte migration into the wound bed is facilitated by focal 
adhesions dependent, integrin-mediated cell-ECM interactions (55). A number of external 
factors can affect this processes and lead to a delayed wound healing. Several conditions, such 
as obesity, nutrition, alcohol consumption, smoking, diabetes, administration of sex hormones, 
age and stress can alter the formation of the wound matrix, affect the availability of oxygen in 
the wound, or lead to decreased levels of pro-inflammatory factors (56). Moreover, it is well 
known that anti-inflammatory agents in therapeutic use, such as glucocorticoids (GCs), are 
associated with decreased proteoglycan synthesis (57).   
II. 2 The dark side of ECM in unhealed wounds 
II.2.1 Tumor stroma orchestrates the onset of cancer  
The inflammatory response is the physiological reaction of the body which occurs following 
tissue damage. However, persistence of acute injury leads to a chronic inflammation which 
predisposes to cancer development. Cancer tissue is a heterocellular system consisting of 
cancer cells themselves and of non-transformed cells with non-cellular ECM components which 
are collectively referred to as stroma (Fig.II.7).  
 
Figure II. 7: Tumor heterogeneity 
Distinct cell types: stromal cells and cancer cells in a reciprocal interaction (58).  
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Cancer initiation is in most cases driven by genetic lesions such as point mutations, gene 
deletion/inactivation, chromosomal rearrangements and amplification, but the role of epigenetic 
modifications is also relevant in causing genetic alterations (59). Epigenetic regulation 
mechanisms are well known to control cellular differentiation. For instance, methylation of CpG 
islands within the genomic sequence leads to transcriptional silencing. Inactivation of the -
Smooth muscle actin (-SMA) gene or of TGF by methylation was shown to impair 
myofibroblast differentiation (60). In turn, lack of epigenetic inactivation of these genes might be 
responsible of a constant myofibroblasts activity, leading to an increased ECM deposition in the 
stroma. Additional studies focusing on the importance of the tumor microenvironment in 
supporting the growth of cancer cells showed loss of tumor-suppressor p53 within the stroma 
(61). Furthermore, irradiated mammary stroma, which is hence affected by mutagenic events, 
was shown to drive the neoplastic behavior of normal, non-irradiated, injected mammary 
epithelial cells resulting in an increased tumor incidence (62).  
 
II.2.2 Role of activated stromal components   
Cancer stroma per se can be the bearer of genetic alterations that may cause spontaneous 
activation of normal fibroblasts in cancer associated fibroblasts (CAFs) (63). The already 
mentioned, the EMT process can occur in presence of growth factors, cytokines and other tumor 
secreted factors (41, 64) and as a consequence local fibroblast or cancer cells (65) can 
transdifferentiate in CAFs with the subsequent acquisition of markers such as -SMA or 
vimentin and the loss of adhesion marker E-cadherin (66). Bone marrow derived progenitor cells 
can also contribute to the formation of CAFs (67). In addition, it was also shown that endothelial 
cells can assume a fibroblasts-like phenotype through endothelial to mesenchymal transition 
(EndMT) (68). The feature that most importantly distinguishes normal fibroblasts from the 
activated ones is the enhanced secretion of ECM proteins, growth factors and proteases 
(Fig.II.8).  




Figure II. 8: Activated fibroblasts 
Physical and biochemical changes occur during the activation of local fibroblasts in a tumor microenvironment. 
Tenascin-C, SPARC, -SMA and a wide range of others molecules are secreted during this transition (69).  
An imbalance of any of these elements triggers irreversible cascades of events. Following a 
feedback mechanism, CAF derived factors can negatively influence adjacent cells within the 
stroma. Esophageal squamous cell carcinoma (ESCC) acquire enhanced invasive properties 
following the exposure to hepatocyte growth factors secreted by CAF cells (70). On the other 
hand, the injection of B16M melanoma cells in mice was shown to create a pre-metastatic niche 
by activating hepatic stellate cells (HSCs), which represent the liver-specific mesenchymal cells 
(71). After exposure to the B16M tumor cell conditioned medium, HSCs secrete matrix 
metalloproteinase-2 (MMP2), known to enhance B16M cell migration in vitro (72).  
II.2.3 Recruitment of mesenchymal stromal cells 
Thus far we have discussed the highly compromised tumor stromal microenvironment with an 
unbalanced secretion of several factors. Stromal or mesenchymal stem cell niches are affected 
in terms of impaired equilibrium between quiescence and proliferation/differentiation. Indeed, in 
primary tumors the features of the niche induces a shift of the mesenchymal stem cells (MSCs) 
from a quiescent to an activated state. In doing so, they represent one of the main regulators of 
cancer stem cells (73) with myofibroblast properties (74). Such MSCs are also actively involved 
in metastatic processes.  
Indeed MSCs provide a permissive microenvironment for the engraftment of tumor cells arriving 
from distant primary sites. In response to several signals released into the circulation from the 
primary tumor, MSCs can generate a pre-metastatic niche already before the arrival of the 
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metastatic tumor cells. For instance, vitronectin and osteonectin produced by osteoblasts within 
the bone metastatic microenvironment have been shown to be strong chemoattractants for 
prostate and breast cancer cell lines (75, 76). Also, higher levels of TGF secreted by breast 
tumor cells contribute to tumor dissemination (77, 78). The use of neutralizing antibodies against 
TNF-, TGF, and VEGF-A in mice injected with Lewis lung carcinoma cells (LLC) was able to 
impair the expression of the two specific pro-inflammatory mediators S100A8 and S100A9 in 
pre-metastatic lungs (79). On the other hand, MSCs can also be recruited from the circulation or 
from the surrounding normal tissue to the tumor-damaged tissue to support the primary tumor 
microenvironment (Fig.II.9) (80). The unique composition of a tumor stromal compartment and 
specific cytokines or growth factors secreted by tumor cells drive the metastatic tropism and the 
ability of cancer cells to spread to other organs. 
  
Figure II. 9: Recruitment of bone marrow stem cells to the primary tumor 
Heterogeneity of a primary tumor microenvironment with many cell types arising from adjacent tissues (80). 
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II.2.4 Cancer: A chronic inflammatory state 
The most prominent indicator for the presence of CAFs is the increase of ECM proteins in the 
stroma. For instance, the non-physiological continuous emergence of cells with a myofibroblast 
phenotype is associated with fibrosis in the liver, where the terminal phase of this process is 
cirrhosis. The increased amount of ECM proteins leads to the collapse of the hepatic 
parenchyma, which is replaced with an enriched collagen tissue (81). The distorted hepatic 
architecture impairs normal liver function. Downstream signaling in response to matrix stiffness 
precedes a functional linkage through which external stimuli are transduced in intracellular 
signals by the cytoskeleton axis. Matrix rigidity transmits forces which regulate signaling 
pathways involved for instance in the control of stem cell differentiation (82),  cell migration (83) 
or also EMT-like processes (84). Among all factors that contribute to tissue stiffness hypoxia 
plays an important role. Indeed, previous reports have shown the association of low oxygen 
tension with an enhanced ECM production in dermal or in rat cardiac fibroblasts (85, 86). On the 
other hand, hypoxia-inducible factors (HIFs) can regulate the expression of matrix 
metalloproteinases, which regulate ECM degradation (87-89). New subfamilies of MMPs are the 
ADAMTS enzymes that unlike MMPs degrade aggrecan at different cleavage sites (90). MMPs 
control the equilibrium between ECM deposition and degradation. However their unbalanced 
expression leads to a continuous degradation of matrix barriers facilitating the invasive behavior 
of cells (89). Furthermore, MMPs are also involved in enhancing neovascularization. In 
particular, the membrane type I metalloprotease MT1-MMP was shown to induce VEGF 
expression (91). As was already mentioned, the ECM fragments released in the stroma after 
MMP-dependent ECM degradation can induce the expression of inflammatory mediators or act 
as chemoattractants for the recruitment of inflammatory cells. For instance specific cryptic sites 
exposed during the fragmentation of fibronectin increase secretion of cytokines such as IL-1, IL-
6 or the tumor necrosis factor (TNF-) (92). TNF- and interleukins IL-1 or IL-6 normally 
suppress cell death, promote epithelial proliferation and activate stem cells during wound 
healing. However, in pathological conditions, the same cytokines have an anti-apoptotic effect 
on premalignant cells, and promote cancer cell proliferation (93). Also, elastin fragments from 
bovine ligaments induce the recruitment of monocytes in lungs of mice (94). ROS originating 
from the inflammatory response have a potential role in causing structural alterations to DNA 
(95) or deregulating methylation patterns (96). A supporting role of fibronectin, laminin, and 
collagen I in stimulating ROS production in human pancreatic adenocarcinoma through the 
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NADPH oxidative activity and the 5-lipoxygenase (5-LO) was also shown (97). ECM and ROS 
cooperation sustain pancreatic cancer cell survival. Collectively, following tissue damage, 
inflammatory mediators act on adjacent cells, which acquire a myofibroblastic phenotype. ECM 
remodeling supports the early stage of tissue repair. However, the incessant activity of all 
stromal components leads to onset of tumor formation (Fig.II.10).  
As mentioned above, HIF not only controls ECM deposition but also processes such as 
angiogenesis, secretion of MMPs and cell survival in general. Therefore, the use of specific 
molecules, such as the topoisomerase I inhibitor topotecan (98) or cardiac glycoside digoxin 
(99) could impair processes triggered in the digoxin was shown to reduce tumor fibrosis by 
inhibiting the activation of the collagen cross-linking enzyme lysyl oxidase (LOX) mediated by 
HIF (99). 
 
Figure II. 10: Tumorigenesis as result of chronic inflammation  
Persistent acute inflammation leads to a failure of the physiological response. In such context, ECM proteins have 
shown an active role during the initiation and progression of cancer (93).   
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II.3 The tenascin family of ECM proteins 
II.3.1 Tenascin proteins in cancer stroma 
Tenascin family proteins are expressed in different types of connective tissues, and are 
composed of four members: tenascin-X, tenascin-C, tenascin-R and the last discovered 
member tenascin-W (100). All tenascin glycoproteins are characterized by a modular structure 
(Fig.II.11) which includes an N-terminal oligomerization region including heptad repeats, 
followed by epidermal growth factor (EGF)-like repeats, a variable number of fibronectin (FN) 
type III domains prone to alternative splicing mechanisms, and a C-terminal fibrinogen-related 
domain (FReD) (101). Via their N-terminal oligomerization domain, tenascin subunits form 
disulfide-linked homo-trimers (tenascin-R and -X) or -hexamers ("hexabrachions"; tenascin-C 
and -W), (Fig.II.11) (102, 103).  
  
Figure II. 11: Graphical representation of the structure of tenascin proteins 
The different tenascin domains were indicated as follows:  heptad repeats (wavy line), EGF-like repeats (diamonds), 
fibronectin type III repeats (squares), and fibrinogen globe (circle). Site of splicing of fibronectin domains is 
highlighted by a black triangle. In addition, electronmicrographs shown on the left, display the hexameric structure of 
tenascin-C and tenascin-W (102).      
Although in general the tissue distribution of tenascins is mutually exclusive, a significant 
overlapping expression pattern of tenascin-C and tenascin-W during embryonic development as 
well as in the adult stage has been observed (Fig.II.12). 
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In 2004, Scherberich and collaborators observed a co-expression of tenascin-C and tenascin-W 
in mouse embryos in smooth muscle cells in the stomach, in the periosteum of the ribs, 
mandible, palate and in teeth while tenascin-C alone was detected in lung, cartilage, liver, and 
brain at the embryonic stages analyzed. (104).  
 
Figure II. 12: Co-expression of Tenascin-C and Tenascin-W in the connective tissue  
Tenascin-C and tenascin-W in connective tissues. (A) Anti-tenascin-C (red) stains cartilage in the neurocranium (c) 
and a salivary gland (sg) in a coronal section through an embryonic mouse head (Day 16.5). Anti-tenascin-W (green) 
stains the connective tissue of a developing muscle of mastication (m). (B) Both tenascin-C (red) and tenascin-W 
(green, with co-localization appearing yellow) are found in the bony matrix of the embryonic mandible (Day 16.5). (C) 
In the adult mouse tenascin-C (red) and tenascin-W (co-localization with tenascin-C is yellow) are found in the 
periosteum (po) of the ribs. Only tenascin-C is detectable in intercostal tendon (t). (100).  
 
The co-localization of tenascin-C and tenascin-W proteins during the embryonic development as 
well as in the adult may reflect overlapping functions. This could be related to their species-
specific presence of the integrin binding site RGD in either tenascin-C or tenascin-W, but never 
in both proteins which could lead to a compensatory effect between them (101).  
The Co-expression of tenascin-C and tenascin-W proteins has been thoroughly investigated 
also in pathological conditions, such as cancer. Both proteins were detected in breast and colon 
cancers. For tumors originating in epithelial organs, it was shown that the cellular sources of 
tenascin-C and tenascin-W were not the tumor cells themselves but cancer associated 
fibroblasts within the stromal cell compartment (Fig.II.13) (105, 106). Moreover, a more 
consistently elevated expression of tenascin-W rather than tenascin-C was detected in the sera 
of patients with colorectal and breast cancers (107). The presence of tenascin-W in the 
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bloodstream of cancer patients and its potential link with blood vessel structures was further 
investigated in 2010 by Martina and co-workers. They were able to observe co-staining of 
tenascin-W with von Willebrand factor in blood vessels of glioblastoma (108). Staining of 
tenascin-C was shown as well; however its localization was more uniformly distributed in the 
tumor tissue (Fig.II.14).   
 
Figure II. 13: Tenascin-C and Tenascin-W in cancer stroma  
Immunostaining of tenascin-C and tenascin-W in colon and breast cancers. H&E staining is shown on the left. In the 
adjacent panels, the brown stain reveals tenascin-C and tenascin-W localization in the tumor stroma (106).   
 
In vitro studies showed an effect of tenascin-C and tenascin-W on endothelial cell behavior. 
Human umbilical vein endothelial cells (HUVECs) seeded on collagen substrata in presence of 
tenascin-W or tenascin-C showed an elongated cell shape, with thin protrusions, typical of 
migratory cells. Additional sprouting of HUVECs was observed when cells were embedded in 
collagen gels containing tenascin-W or tenascin-C (108).  
Tenascin-W and tenascin-C proteins were also detected in many other human solid tumors: 
pancreas, kidney, lung and melanoma (109). Figure II.14 (B) shows the immunohistochemical 
analysis of tenascin-C and tenascin-W in lung tumor sections. Tenascin-C also appeared in 
normal lung tissue highlighting the fact that tenascin-W is a better tumor biomarker since it was 
exclusively expressed in the stroma of lung tumor sections and not in the healthy parts of the 
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lungs of the same patients. In addition, a wide number of other tumor types, such as kidney, 
colon, breast, ovary, prostate, and lung (Fig.II.14) showed a co-localization of tenascin-W with 






Figure II. 14: Tenascin-W involved in angiogenesis  
(A) Immunofluorescence of tenascin-C and tenascin-W in glioblastoma (108); white stars mark desmin-positive 
pericytes. (B) Panel B shows the immunohistochemical analysis of tenascin-C and tenascin-W in normal and tumor 
lung sections. (C) Panel C shows cryosections of a lung tumor co-stained for tenascin-W (first panel; red) and for the 
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Despite the existence of a considerable similarity between tenascin-C and tenascin-W, in 
general, the expression of tenascin proteins is tissue-specific and each of the tenascin family 
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Extracellular matrix proteins of the tenascin family resemble each other in their domain 
structure, and also share functions in modulating cell adhesion and cellular responses to growth 
factors. Despite of these common features, the four vertebrate tenascins exhibit vastly different 
expression patterns. Tenascin-R is specific to the central nervous system. Tenascin- C is an 
"oncofetal" protein controlled by many stimuli (growth factors, cytokines, mechanical stress), but 
with restricted occurrence in space and time. In contrast, tenascin-X is a constitutive component 
of connective tissues, and its level is barely affected by external factors. Finally, the expression 
of tenascin-W is similar to that of tenascin-C but even more limited. In accordance with their 
highly regulated expression, the promoters of the tenascin-C and -W genes contain TATA 
boxes, whereas those of the other two tenascins do not. This article summarizes what is 
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1. Introduction: The tenascin gene family 
Tenascins are a family of large, oligomeric, multi-domain extracellular matrix proteins (1). Four 
genes encoding tenascin-C, -R, -X, and -W proteins exist in higher vertebrates, and a single 
tenascin gene is found in cephalochordates whereas similar genes and proteins do not seem to 
exist in lower animals (2) (3, 4). Tenascins are characterized by their unique domain structure. 
Each monomeric unit comprises an N-terminus with heptad repeats flanked by cysteine 
residues. This N-terminal oligomerization region is followed by EGF-like repeats, and a variable 
number of fibronectin (FN) type III repeats as a result of alternative mRNA splicing. At the C-
terminus, each subunit ends with a large C-terminal fibrinogen related domain (1). Via their N-
terminal oligomerization domain, tenascin subunits form disulfide-linked homo-trimers (tenascin-
R and -X) or -hexamers ("hexabrachions"; tenascin-C and -W). Rather than representing bona 
fide structural components of the extracellular matrix, three of the four tenascins are 
"matricellular" proteins (4) involved in modifying the interaction of cells with extracellular matrix 
and growth factors, and hence regulating cell adhesion, migration, growth and differentiation in a 
context-dependent manner (5); see other articles in this issue). The exception is tenascin-X, 
which helps to bridge collagen fibrils (6) and thereby organizes the fibers, as evidenced by 
human mutations in this gene that cause Ehlers-Danlos syndrome (7). 
 Except for tenascin-X, which has a widespread distribution like many ECM proteins, the 
other three tenascins show a very restricted pattern of expression during embryogenesis, tissue 
remodeling and tumor formation (8-11). Their specific patterns of localization, which are specific 
for each of the four family members, point to tightly controlled spatial and temporal expression, 
and are likely to reflect a complex gene regulation. This brief article reviews the expression 
patterns of the four tenascins in development, regeneration and disease, with a particular focus 
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2. Tenascin-C: Expression in organogenesis, inflammation and cancer 
2.1. Expression patterns of tenascin-C in development and disease 
Tenascin-C, the founding member of the protein family, received much attention after its 
discovery because of its highly specific and restricted expression patterns during vertebrate 
embryogenesis (12, 13). Whereas many other ECM proteins exhibit a ubiquitous distribution in 
the mesenchyme with only gradual differences, tenascin-C is often expressed in an all-or-none 
fashion both in space and time. Specifically, this protein is found in the mesenchyme around 
primordia of most epithelial organs right at the time of early morphogenesis (13). In addition, 
tenascin-C is associated primarily with development of the musculo-skeletal system, where it is 
an early marker of tendon, ligament and bone formation (12). Other prominent sources of the 
protein are neural crest cells in early embryos (14), neural crest derived Schwann cell 
precursors in developing peripheral nerves (15, 16) and vascular smooth muscle cells around 
developing arteries (17). 
 In the adult, tenascin-C is restricted to few tissues bearing high tensile stress (tendons, 
ligaments, periosteum, arterial walls) (18, 19), and interestingly to certain stem cell niches (20). 
However, the protein becomes prominently expressed de novo in practically every tissue upon 
chemical or mechanical injury, as well as in other pathological processes associated with 
inflammation and/or mechanical stress, not the least tumor and metastasis formation (1). 
 These findings indicate that the tenascin-C gene must undergo complex regulation 
encompassing 1. patterning genes in early morphogenesis, 2. paracrine growth factors 
regulating the communication between different cell types in organogenesis, 3. inflammatory 
mediators, and 4. mechanical stress. Published evidence is summarized in the following 
paragraphs. 
2.2. Structure of the tenascin-C (TNC) gene 
The human tenascin-C gene (gene ID: 3371) is found on chromosome 9q33; it contains 29 
exons of which 9 (each coding for a FN3 domain) can be alternatively spliced (21-23). The 
transcript starts with a non-coding exon, separated by an intron >20 kb long, and followed by 
exon 2, which contains the ATG start codon for translation initiation. Tenascin-C mRNA from 
human fibroblasts and human melanoma cells analyzed by primer extension and S1 nuclease 
showed a single transcription start site (TSS) localized to the first exon. Sequencing of 
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approximatively 2300 bp of the tenascin-C      5’-flanking region has revealed several 
potential binding sites for transcription factors (see below) (21). The sequence of 220 bp 
upstream to the TSS was identified as region with high promoter activity; it contains a classical 
TATA box at -20 to -26 bp. A putative silencer sequence was localized to the fragment between 
-220 and -2300 bp (21). Similarly, primer extension analysis of mRNA isolated from brain tissue 
of mouse embryos showed a single TSS that lays 27 bp downstream of the TATA box (24). 
Moreover, the 230 bp proximal promoter sequence, which is conserved between species, was 
found to be highly active in driving reporter gene expression when transfected into both mouse 
and human fibroblasts (24). The chicken TNC (cytotactin) gene features a TATA box at a similar 
position as the mammalian counterparts (25) A comparison between the human, mouse and 
chicken TNC promoters has been summarized by Jones and Jones (2000) (19). 
2.3. Tenascin-C gene regulation by patterning genes 
During vertebrate embryogenesis, tenascin-C is often expressed in distinct spatial and temporal 
patterns associated with morphogenetic events, e.g. during somatogenesis, segmental nerve 
formation (16), mammary gland (26), tooth (27), kidney (28) and lung (29) development. It was 
therefore an obvious possibility that the TNC gene could be controlled by transcription factors 
encoded by segmentation and patterning genes. Indeed, some of the early publications on 
tenascin-C promoters from different species investigated their regulation by homeobox 
transcription factors. For example, the chick promoter was found to be strongly activated by co-
transfection of fibroblasts with even-skipped homeobox 1 (Evx1), and by mutational analysis, an 
AP-1 element at -275 bp was identified that was essential for this response (30). The same AP-
1 site was required for induction of the promoter by serum; Evx1 overexpression potentiated the 
effect of serum. Thus, Evx1 appears to activate the tenascin-C gene indirectly by synergizing 
with jun/fos transcription factors, which target the AP-1 site.  
 On the other hand, a homeobox transcription factor involved in anterior head formation, 
orthodenticle homolog 2 (Otx2), was shown to bind directly and with high affinity to a target 
sequence in the human tenascin-C promoter and to suppress its transcriptional activity (31, 32); 
the Otx2 target sequence is conserved at -550 bp in the mouse (but not chick) gene. Similarly, 
the POU-homeodomain transcription factor Pou3f2 (also called Brn2 or Oct-7) was 
demonstrated to interact directly with a reverse octamer sequence (ATGCAAAT) present at -200 
bp in the mouse tenascin-C promoter, which is conserved in the human and also the chick gene. 
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Transfection with Pou3f2 (Brn2) expression vector stimulated transcription from the tenascin-C 
promoter in a neuroblastoma cell line, but had no effect in glioma cells (33). 
 In addition, the proximal promoter of the chick, mouse and human tenascin-C gene 
contains another conserved homeodomain binding sequence (HBS) at -45/-60 bp (19). 
Transcription factor paired-related homeobox 1 (Prrx1; formerly called Prx1 or Mhox) is often co-
expressed with tenascin C, and overexpression of Prrx1 strongly induced a full-length mouse 
tenascin-C promoter construct in a vascular smooth muscle cell line (34). Later, Prrx1 was 
demonstrated to transactivate tenascin-C gene transcription in mouse pulmonary endothelial 
cells through direct interaction with the HBS located within the proximal promoter (35). 
Increased deposition of tenascin-C expression along the arterial wall in pulmonary vascular 
lesions of patients with mutated BMP type II receptors was highly associated with the 
expression of Prx1 (36).Tenascin-C is a prominent early marker for developing tendons, which 
form according to intricate patterns during trunk and limb morphogenesis (12). The basic helix-
loop-helix transcription factor scleraxis (Scx) is also expressed specifically in all embryonic 
tendons, and was shown to be essential for development and differentiation primarily of long 
load-bearing tendons (37). Tenascin-C was therefore assumed to be a target gene of this 
tendon-specific transcription factor. Indeed, myocyte enhancer factor 2C (mef2c) and scleraxis 
were reported to synergize in inducing tenascin-C expression during tendon development in 
Xenopus, although the exact mechanism on the gene promoter level was not examined (38). 
However, scleraxis is not strictly required for tenascin-C production in developing tendons: In 
scleraxis null embryos, tenascin-C was still found to accumulate in condensing mesenchyme at 
positions where tendons normally develop (37). Therefore, although scleraxis might boost its 
expression, the tenascin-C gene appears to be controlled by additional factors that act even 
upstream of scleraxis during early tendon morphogenesis.  
2.4. Tenascin-C gene regulation by growth factors and inflammatory mediators 
TGF-β    y      m                            x            m    x          x                
development and in pathologies (39, 40). Stimulation of tenascin-C synthesis has been detected 
after treatment of chick embryo fibroblasts with TGF-β1 (41), and this growth factor is also 
associated with the enrichment of tenascin-C in the stroma of malignant breast tumors (42, 43). 
SOX4 is a transcription factor overexpressed in many human tumors and tenascin-C was 
identified as a direct SOX4 target gene (44). Through gene set enrichment analysis it was found 
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that direct target genes of TGFβ–induced SMAD3 are also enriched in the list of the SOX4 
target genes. In the context of malignancies, this would suggest a cooperation between SOX4 
and TGF-β1                        -C expression. A direct role of TGF-β       m              -C 
expression was observed in mammary epithelial cells (HC11) and in mouse embryo fibroblasts 
(45). For astrocytes, it was shown that the expression of tenascin-C is controlled by the 
canonical Smad-mediated TGF-β                 y     by   b  b                   ( GF) (46). 
S         5’-deletions of the human tenascin-C    m                                5’-CAGA-3’ 
motif capable of binding Smad2/Smad3 in the region between -248bp and +75 bp (47). In 
addition, it was shown that Smads interact with co-factors such as Sp1 or Ets1 and CBP/p300, 
which possess binding sites located within the same promoter region, in order to achieve proper 
tenascin-C gene transcription induced by TGF-β      m      m     b  b      (47). 
 In the same cells, platelet-derived growth factor (PDGF) regulates tenascin-C gene 
expression via PI3K/Akt signaling, which triggers the interaction of transcription factors Sp1 and 
Ets1/Ets2 in an active complex that recognizes Ets binding sites (EBS) in the promoter (48). Ets 
binding sites within the tenascin-C promoter were also shown to be the targets of EWS-ETS 
transcription factor. EWS-ETS is a chimeric gene found in several tumor types such as Ewing 
sarcoma and peripheral primitive neuroectodermal tumors (PNETs) (49). In a similar setting, 
oncogenic transformation of primary rat embryonic fibroblasts can be the consequence of the 
activity of transcription factor c-Jun in cooperation with an activated ras gene (50). The transitory 
expression of tenascin-C induced by c-Jun could facilitate the de-adhesion of fibroblasts from 
the extracellular matrix, thus promoting their transformation. The c-Jun transcription factor 
contains a bipartite DNA binding domain which recognizes GCN4/AP1 and NF-κ  b       
sequences, located in the tenascin-C promoter region from -220 to +79 (50). 
  Notch is a large transmembrane protein that acts as receptor for cell-bound 
ligands Delta and Jagged; upon activation, its intracellular domain is cleaved and translocates to 
the nucleus where it acts as transcriptional regulator through binding to RBPJk/CSL (51). A 102-
b    q      5’    m                                       m           -C gene includes an 
RBPJk/CSL binding sequence (GTGGGAA) responsible for Notch2-mediated transactivation in 
glioblastomas (52). Conversely, in lung metastases of breast cancer, tenascin-C expression has 
been implicated in supporting the Notch signaling pathway. Indeed, the enrichment in the 
metastastic stroma of musashi homolog 1 (MSl1), an adult stem cell marker induced by 
tenascin-C, acts as positive regulator of Notch (53). In addition to MSl1 expression, high levels 
38  II. Introduction 
 
 
of JAG1 ligands mediate Notch signaling in human breast cancer (Michael Reedijk, et al.) 
Taking the two findings together, there may be a positive feedback between Notch and 
tenascin-C expression, which in turn will further amplify the Notch signaling pathway.  
 A number of cytokines has been shown to induce tenascin-C expression in various cell 
types; among them are both pro-inflammatory such as IL-1α (54) and IL-1β (55), as well as anti-
inflammatory e.g. IL-4 (56) and IL-13 (57). Cytokines signal via various intracellular pathways, 
most notably Jak/Stat, MAPK, and NF-κ  (58, 59). Pro-inflammatory cytokines such as IL-1 and 
TNF-α    m    j                                                   m                (RA) (60), and 
high levels of these mediators are correlated with the upregulation of tenascin-C protein in RA 
synovium (61). Transcriptional regulation of the tenascin-C gene by interleukins has not been 
analyzed in detail yet, but it is reasonable to assume that some of the previously mentioned cis-
acting elements (NFkB, AP1, Ets, AP1) in its promoter are involved. Along these lines, a high 
level of tenascin-C protein expression has also been shown in immune myeloid cells upon 
exposure to the bacterial cell wall component LPS, which in turn stimulates the pathogen-
associated molecular pattern (PAMP) receptor, toll-like receptor-4 (TLR4) (62). TLR4 can also 
be activated by auto-antigens in the course of RA, and AKT/PI3K and NF-κ        y  
triggered by TLR4 were demonstrated to induce transcription of tenascin-C in synovial 
fibroblasts and myeloid cells in this case (63). In addition to the known element in the proximal 
promoter, many additional potential binding sites for NF-κ                                   
               5’        m   q                                             -C gene (63), but their 
exact role in the response to inflammatory mediators needs to be established.  
 Interestingly, based on a positive feedback mechanism, tenascin-C can in turn bind to 
and activate TLR4 through its fibrinogen-like globe (64). Therefore, tenascin-C can act directly 
as inflammatory stimulus, facilitating also inflammatory cell infiltration. Tenascin-C was also 
detected in the synovial fluid of osteoarthritic (OA) cartilage and its expression is correlated with 
proteoglycan loss from the articular cartilage (65). Following the activation of TLR4 by tenascin-
C, a series of inflammatory mediators and proteases such as ADAMST4 promote matrix 
degradation in OA joints. Secreted tenascin-C protein was found in conditioned media of 
cartilage in culture upon IL-1a treatment (65). Tenascin-C is also involved in hepatic ischemia 
/reperfusion injury (IRI). In mice deficient for TLR4 and tenascin-C, a downregulation of MMP-9 
and cytokines IL-6, IL-1b and CXCL2 was observed. Mice deficient in TLR4 and tenascin-C 
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were characterized by low liver damage and a significantly higher liver regeneration in this 
model (66). 
Glucocorticoids are potent anti-inflammatory steroid hormones. They function by binding to 
nuclear receptors that act as transcription factors, but can also negatively regulate gene 
expression by inhibiting the activity of other factors like AP1 and NFkB (67). Glucocorticoids 
have also been described as important hormones involved in myelopoiesis, and they can 
directly act at the progenitor cell level or by modifying the expression of ECM components. 
Down-regulation of tenascin-C expression by glucocorticoids was shown in bone marrow 
stromal cells (68). These authors suggested that the different tenascin-C distribution between 
bone marrow of newborn and adult mice controlled by glucocorticoids might in part influence the 
hematopoiesis process. A putative binding site for glucocorticoid receptors is located at position 
-985 of the chicken tenascin-C promoter sequence (69), but its function in the hormone 
response has not been explored. 
 A further repressor motif was mapped to position -467 to 460 of the human tenascin-C 
promoter that was demonstrated to bind GATA6, a zinc finger transcription factor known to 
regulate the synthetic phenotype of vascular smooth muscle cells. Exogenous expression of 
GATA6 in dermal fibroblasts negatively modulated the level of tenascin-C protein, and inhibited 
its induction by IL-4 and TGF- (70). 
2.5. tenascin-C gene regulation by mechanical stress 
Whereas tenascin-C is expressed transiently in many developing organs, it persists in the adult 
mainly in a few structures bearing high tensile stress, such as tendons, ligaments, and the 
smooth muscle walls of arteries (18, 19). It was therefore speculated early on that its gene might 
be regulated by mechanical forces. Indeed, tenascin-C expression was found to be induced in 
vivo e.g. by hypertension in the arterial walls of rats (71), or upon supra-physiological loading in 
skeletal muscle connective tissue of chick (72), rat (73) and human (74). Transduction of 
external mechanical stimuli requires integrins as bridges between ECM and the cytoskeleton 
(75). Depending on the precise nature of the stimulus, various integrin-dependent signaling 
pathways can then be triggered, such as Ca influx, activation of Erk1/2, NFkB, and RhoA/ROCK 
(76). An extensively studied mechanotransduction pathway concerns the rapid activation of the 
tenascin-C gene by cyclic strain (10%, 0.3 Hz for 1-6 h) in fibroblasts attached to elastic 
substrates, which depends on Rho/Rock signaling (77). Pericellular fibronectin, integrin α5β1 
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(78) and integrin-linked kinase (ILK) (79) were shown to be required for RhoA activation and 
tenascin-C induction in response to cyclic stretch in mouse fibroblasts. Strain-mediated Rho A 
activation triggered an increase in cellular actin assembly (80), which in turn lead to 
translocation of megakaryoblastic leukemia-1 (MKL1; also called MAL or MRTF-A) from the 
cytoplasm to the nucleus (79), where it is known to act as a trancriptional regulator (81). 
Accordingly, tenascin-C induction by cyclic strain was abolished by MKL1 knockdown in NIH3T3 
fibroblasts (82). MKL1 regulates the transcriptional activity of serum response factor (SRF) (83). 
Indeed, the mouse tenascin-C promoter contains a serum response element (SRE; CArG-box) 
located 1414bp upstream from the transcription start site, which is in part involved in its 
activation. However, tenascin-C induction by cyclic strain was found to be independent of SRF 
but strictly dependent on the interaction of the SAP domain of MKL1, a putative DNA-binding 
domain, with the proximal tenascin-C promoter (82).  
 Among vascular diseases, hypertension is correlated with elevated tenascin-C 
abundance around vessels, concomitantly with an increase in wall stress. In human arterial 
smooth muscle cells, cyclic strain (13%, 0.5 Hz for 24 h) was found to control the expression 
and activity of nuclear factor of activated T cells 5 (NFAT5) in a JNK-dependent manner (84). 
Once translocated into the nucleus in response to strain, NFAT5 was able to induce tenascin-C 
gene expression. Five NFAT consensus sequences were found in the first 3512 bp of the 
human tenascin-C promoter sequence upstream of the transcription start site, and for the first of 
them (at -820 bp), cyclic strain-induced binding was demonstrated by ChIP analysis (84). Note 
that the Rho/MKL1 pathway described above directly activates the tenascin-C gene within 1-3 
hours in response to strain, whereas the JNK/NFAT5 pathway requires prior synthesis of a 
transcription factor and takes 24 h for tenascin-C induction. 
 Yet a different mechanotransduction pathway was found to be responsible for tenascin-C 
induction by cyclic strain in rat cardiomyocytes. It is noteworthy that a similar strain amplitude 
(9-14%) but a higher frequency (1 Hz) was used (85). In this case, the response depended on 
release of reactive oxygen species and activation of NFkB. A consensus sequence for this 
transcription factor at -210 bp was required for mechanical activation of the tenascin-C 
promoter, and shown to bind the p50 subunit of NFkB in response to strain (85). Moreover, 
tenascin-C expression is not only regulated by dynamic (cyclic) strain, but also by static tensile 
stress. For example, tenascin-C expression by fibroblasts is high when they are embedded in 
an attached (stressed) collagen matrix, but diminished when the matrix is released from its 
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anchors (relaxed). A conserved DNA motif (GAGACC) at -550 bp in the the tenascin-C promoter 
was required for this response (69). This motif is present in the control regions of other 
mechanoresponsive genes where it is recognized by NFkB (86), but the factors binding to it in 
the tenascin-C promoter have not been identified. In any case, these examples show that 
depending on the cell type and on the exact mode and doses of mechanical stress, the 
tenascin-C gene appears to be regulated via distinct mechanotransduction pathways. 
 In chick embryo fibroblasts, PDGF and TGF growth factors were shown to act in an 
additive manner with tensile strain in promoting tenascin-C mRNA expression (77), and thus an 
increase in these factors might indirectly stimulate tenascin-C production in response to 
mechanical load. For example, tenascin-C accumulates in angiotensin II- induced perivascular 
fibrotic lesions in hypertensive mice. Angiotensin II was shown to trigger aldosterone-induced 
inflammation, which indirectly stimulated tenascin-C expression by upregulating PDGF-A/B, 
PDGF receptor a, and TGF1 in this model (87). 
2.6. Posttranscriptional regulation of tenascin-C gene by microRNAs 
Although this article focuses on transcriptional control of tenascin genes, it is important to note 
that other regulatory mechanisms are important as well. The role of microRNAs as regulators of 
post-transcriptional gene silencing is well documented (88, 89), and recent studies have shown 
that the repression of certain microRNAs corresponds to a more pronounced tumorigenesis 
(90). For example, downregulation of SOX4 and tenascin-C is controlled by miR-335, and loss 
of this microRNA in breast cancer was shown to induce metastasis in part by increased 
tenascin-C levels (91). Other findings show how tenascin-C promotes oncosphere formation by 
a metastasis-initiating breast cancer cell population for lung colonization, and in this context, 
GATA3 and miR-335 were downregulated (53). Conversely, the ectopic expression of some 
microRNAs turns out in a decreased metastatic potential. For instance, the rescued expression 
of miR-126 suppresses lung and bone metastasis by human breast cancer cells through 
targeting tenascin-C. Bioinformatic analysis has yielded target sequences for microRNAs 
b              3’  TR             -C gene, explaining how the interaction can occur (91). 
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3. Tenascin-R: An ECM protein mainly restricted to the central nervous system 
3.1. Expression patterns of tenascin-R (TNR) in CNS development, injury and cancer 
Tenascin-R, originally designated as janusin in rodents and restrictin in chicken, is almost 
exclusively located to the central nervous system (92-95), but transiently appears also in 
Schwann cells during peripheral nerve development (96). Previous work has shown two 
tenascin-R molecular isoforms (splice variants) of 160 and 180 kDa expressed in the CNS by 
oligodendrocytes and a few neuronal cell types, but not by astrocytes or fibroblasts (97). In the 
developing human cortex, the spatiotemporal distribution of tenascin-R parallels neuronal 
migration (98). In vitro experiments have demonstrated that tenascin-R promotes adhesion and 
differentiation of oligodendrocytes and astrocytes by binding to sulfatides on cell surfaces (95, 
99). Conversely, tenascin-R can inhibit neurite outgrowth either by interacting with adhesion 
molecule contactin 1 (F3/F11) or by interfering with integrin-dependent adhesion to fibronectin 
(reviewed in (100).  
 In a pathological context, activation of microglial cells after facial nerve axotomy in rats 
has been shown to downregulate tenascin-R protein expression with the subsequent loss of its 
anti-adhesive properties (101). On the other hand, tenascin-R is up-regulated in the injured 
visual pathway of the lizard that has the capacity to regenerate (102). In brain cancer, tenascin-
R was reported to be overexpressed in pilocytic astrocytoma, oligodendroglioma and 
ganglioglioma, but not glioblastoma (103). 
3.2. Structure of the tenascin-R (TNR) gene 
The human TNR gene (gene ID: 7143) is located on chromosome 1q24 and has 23 exons. The 
human, rat and mouse genes show homologous sequences of exons 1, 2 and 3 of which the 
first two are noncoding and the latter contains the ATG start codon (104, 105). Exon 1 and 
167 bp upstream of this exon were sufficient for full and cell type-specific activity of the tenascin-
R promoter in cell culture (Leprini, Gherzi et al. 1998; Gherzi, Leprini et al. 1998; Putthoff, Akyuz 
et al. 2003). The TATA-less tenascin-R promoter displays canonical binding sites for potential 
regulators such as GATA-1, GATA-2, CREB, AP1 and p53 transcription factors as well as 
glucocorticoid receptors (105, 106). However, their functional relevance has not been 
addressed.  
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3.3. Tenascin-R gene regulation by growth factors 
In mice, oligodendrocyte precursor cells synthesize most tenascin-R, whereas expression 
decreases with differentiation. In more mature oligodendrocytes, expression of TNR was 
stimulated by coculture with astrocytes or neurons, and was also induced by adding platelet-
derived growth factor (PDGF) but not basic fibroblast growth factor (107). Rat 
pheochromocytoma cells (PC12) express high levels of TNR mRNA after nerve growth factor 
(NGF) treatment (92, 107). In contrast, oligodendrocytes treated with conditioned medium from 
activated microglia show a reduced TNR mRNA expression due to the release of injury factors 
such as TNF-α (101). Unfortunately, there are no studies yet how these growth factors and 
cytokines regulate the TNR gene on the promoter level. 
4. Tenascin-X: A regulatory component of collagen fibers 
4.1. Expression patterns of tenascin-X in collagen-rich tissues 
Tenascin-X was discovered as a gene of the MHCIII locus overlapping with the CYP21A2 gene, 
which encodes steroid 21-hydroxylase (7, 108). CYP21A2 mutations cause congenital adrenal 
hyperplasia, but a fraction of cases with deletions in this genomic region is also deficient for 
tenascin-X; these patients suffer in addition from hyperextensible skin and joint laxity typical of 
Ehlers Danlos syndrome (109). Deletion of the tenascin-X (Tnxb) gene in mice was 
subsequently shown to phenocopy the connective tissue defects observed in affected human 
patients (110). Thus, in apparent contrast to the other tenascins, the tenascin-X protein has a 
clear structural role in connective tissue integrity by binding (indirectly) to collagen fibers and 
regulating collagen deposition in vivo (6, 111, 112). During embryonic development, TNXB 
mRNA is especially prominent in the epicardium, skeletal muscle connective tissue, and tendon 
primordia (113). In the adult, TNXB mRNA becomes widely and constitutively expressed in most 
connective tissues, but is present at higher levels in tendons, ligaments, and perineural sheaths 
(Geffrotin 1995). Despite of considerable overlap on the tissue level especially in the embryo, on 
a smaller scale the distribution of tenascin-X mRNA and protein was found to be distinct and 
often reciprocal to that of tenascin-C (9). Interestingly, also in the context of malignancy 
tenascin-X and tenascin-C appear to be regulated in opposite ways. For example, tenascin-X 
expression is prominent in normal skin but strongly suppressed in cutaneous melanoma, where 
tenascin-C is highly up-regulated (114). In contrast to tenascin-C, tenascin-X is not induced in 
breast and ovarian carcinomas, but has been reported to be a marker for malignant 
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mesothelioma (115). Also strikingly different from tenascin-C, there are no reports indicating an 
induction of tenascin-X expression in inflammation or wound healing. 
4.2. Structure of the tenascin-X (TNXB) gene 
In humans as well as rodents, there are two tenascin-X genes of which TNXA is a pseudogene. 
In the human genome TNXB (gene ID: 7148), the gene coding for TNX protein, is located on 
chromosome 6p21.3 in the neighborhood of TNXA. The TNXB gene counts 44 exons, and its 
structure appears to be unique among all tenascins since transcription can take place from three 
different promoters which lack TATA or CAAT boxes. In human fetal adrenal gland and muscle, 
the major transcript starts with the first untranslated exon located more than 10 kb upstream 
from the second exon containing the translation start codon (116). In contrast, in human NCI-
H295 adrenocortical carcinoma cells TNXB expression is controlled by two additional promoters. 
TNXB transcripts can be initiated either from the same promoter as for an upstream gene, the 
Creb-related protein (CREB-RP; gene name ATF6B),       m                 3’        ATF6B. 
Both events produce transcripts with alternative first untranslated exons that are differentially 
spliced (116). Further analysis of 375 bp upstream of the noncoding first exon of the major 
transcript identified several putative binding sites for Sp1/Sp3 transcription factors, of which two 
were proven to be functional and required for driving TNXB expression in fibroblasts (117). 
Similarly, an Sp1 site 140 bp upstream of the major transcription start site of the mouse 
tenascin-X promoter was shown to play a critical role in expression of this gene (118). 
4.3. Tenascin-X gene regulation by growth factors 
Unlike for the other proteins belonging to the tenascin family, there are so far no reports 
indicating that tenascin-X is regulated by growth factors or cytokines. Thus, the signaling 
pathways that act on the Sp1/Sp3 sites described above in the tenascin-X promoter are at 
present unknown. Like tenascin-C and tenascin-W, however, tenascin-X is subjected to 
negative regulation by glucocorticoids (119), but again the mechanism has not been elucidated 
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5. Tenascin-W: Expression in osteogenesis and tumorigenesis 
5.1. Expression patterns of tenascin-W (TNW) in bone formation and cancer 
Tenascin-C and tenascin-W proteins show a partially overlapping expression pattern in the 
developing and adult skeleton (120). Most of the research based on the regulation of TNW 
expression in a physiological context indicates its significant role in osteogenesis (10). In the 
adult organisms, TNW is predominantly expressed in cancer stroma of most solid tumors 
(Scherberich, Tucker et al. 2005; Degen, Brellier et al. 2007; Degen, Brellier et al. 2008; 
Martina, Chiquet-Ehrismann et al. 2010) and represents an even more specific tumor marker 
than tenascin-C (10, 11, 45, 121, 122). 
5.2. Structure of the tenascin-W (TNN) gene 
Tenascin-W was first discovered and cloned from zebrafish (123). Unfortunately, its mouse 
ortholog (124) was subsequently called tenascin-N (Tnn) (125), and this is now the official gene 
name in the NCBI data bank. The complete characterization of the human tenascin-W gene 
(TNN; gene ID: 63923) was carried out in 2007 (121). The human TN-W gene consists of a total 
of 19 exons spanning 80 kb of genomic DNA. The transcript starts with a non-coding exon. The 
transcription start site (TSS) is 79bp upstream the exon2, which contains the start codon ATG 
(126) The region comprised within -957 and -79bp from the transcription start site as well as a 
conserved region within the first intron are involved in transcription regulation, and specifically, 
the minimal basal promoter sequence is contained in the last 79bp fragment (126). 
5.3. TNN gene regulation by growth factors 
BMP2 is able to induce tenascin-W expression in periosteum during the endochondral bone 
formation in mice (127). An in vitro system of Kusa-A1 cells shows an increase of TNN 
transcript starting with the differentiation in osteoblasts (128). Mouse myoblasts (C2C12) 
differentiate into osteoblastic cells upon treatment with bone morphogenetic protein 2 (BMP2) 
and concomitantly they express tenascin-W (124). The induction of tenascin-W synthesis by 
BMP2 in MEF as well as in HC11 cells occurs via non-canonical p38 MAPK signaling pathway 
(45). Tenascin-W was also strongly induced by Bmp7 in embryonic cranial fibroblasts in vitro 
(129). Among other regulators of bone formation, Wnt5a signaling is indirectly involved in 
promoting TNW expression through p38 activation of an unknown TNW inducer, thus controlling 
bone density (130).  
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TGF1 and its receptor ALK5 were identified as important factors for human TNW gene 
transcription in human bone marrow stem cells (BMSCs) (126). Computational analysis shows 
the presence of a SMAD4 nuclear transcription factor binding site at -61bp from the TSS, in 
proximity of a TATA box sequence and site-directed mutagenesis of the SMAD4 binding site 
strongly impaired the SEAP reporter gene expression driven by the minimal basal promoter 
(126). Finally, similar to tenascin-C and tenascin-X, the expression of tenascin-W is also 
inhibited by glucocorticoids. In this case a negative glucocorticoid response element was 
identified in a conserved region of the first intron, displaying a glucocorticoid-dependent 
repressive action on the proximal tenascin-W promoter (126).  
6. Conclusions and outlook 
The four members of the vertebrate tenascin family are quite similar not only in their overall 
domain organization, but as typical "matricellular" proteins also appear to fulfill similar functions: 
There is increasing evidence that they all modulate cell adhesion and cellular responses to 
growth factors and cytokines in a context-dependent manner (1). In view of these structural and 
functional similarities, it is surprising that the four tenascins exhibit vastly different expression 
pattern in space and time. Tenascin-R is almost exclusively found in the central nervous system 
and its expression level is affected by just a few known growth factors. In contrast, tenascin-C is 
an "oncofetal" or "stress" protein that is controlled by many stimuli, can appear in almost any 
tissue and cell type in the embryo and the adult, however just at certain times and in specific 
locations. Tenascin-X is a constitutive component of most connective tissues and its level is 
barely influenced by growth factors, whereas the expression of tenascin-W is again more similar 
to that of tenascin-C, although it is even more restricted to developing/remodeling bone, certain 
stem cell niches (20), and to a subset of tumors. These observations point to very distinct 
mechanisms of regulation for the various family members. Fitting with a highly regulated versus 
a more constitutive expression, respectively, the gene promoters of tenascin-C and TNW have 
classical TATA boxes ca. 20-40 bp upstream of their transcription start sites, whereas the 
promoters of TNR and TNX are TATA-less. Tenascin-C and TNR genes have a first 
untranslated exon separated from the second ATG-containing exon by a very large intron, which 
is likely to be involved in gene regulation. TNR has two untranslated exons and the ATG 
translation start site is found in the third, whereas TNX even possesses three alternative 
promoters and non-coding first exons that are subjected to alternative splicing (see above). 
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Because the tenascin-C gene was the first of the family to be characterized, most is known 
about its regulation, although it turns out to be overwhelmingly complex. The responsiveness of 
the tenascin-C gene to segmentation genes, growth factors/cytokines and mechanical stress 
appears to be very similar in different vertebrate species, which is reflected in the high sequence 
similarity in parts of the promoter regions. Nevertheless, although many of the same cis-acting 
regulatory elements have been identified in the chick, mouse and human tenascin-C promoter, 
there appear to be differences in their arrangement and activity (19). Although TNW is quite 
distantly related to tenascin-C within this protein family, its expression pattern and the regulation 
of its gene appears to be most similar to that of tenascin-C, especially also in stem cell niches 
(131) and in cancer. Future research is likely to reveal more about similarities and differences in 
the control of these two genes e.g. by TGF-βs versus BMPs, or by various cytokines. 
Conversely, TNR is the closest family member of tenascin-C on the protein level, but it is 
regulated completely differently. It is remarkable that only about 200 bp of the proximal promoter 
and sequences in the first exon of the TNR gene are necessary and sufficient for its expression 
exclusively in neuronal cells (105). Thus, this gene appears to represent a relatively simple case 
of tissue-specific regulation, and it will be interesting to work out the exact mechanism. As for 
TNX, it exhibits a constitutive expression more like TNR, but in a reciprocal fashion since it is 
found in most tissues except the CNS. Nothing is known yet about the mechanism for tissue-
specific expression of this gene, and the lack of regulation by growth factors and the relative 
scarcity of putative cis-acting elements in its promoter are noteworthy (117). For more 
meaningful comparisons between the genes of this family, it would be important learn more 
about the regulation of TNR, TNX and TNW genes in the future. In the case of tenascin-C, 
systems biology and computational approaches will probably be required to fully understand 
how a dozen or more signaling pathways converge to control its very complex gene promoter. 
 Why is it relevant to study the regulation of tenascins in even more detail? TNR and 
TNX, because of their largely constitutive expression, might perhaps be less interesting in this 
respect. Of course, TNX will remain in focus because of its important function in tissue integrity 
and its association with human disease, and TNR might be further investigated as a prime 
example for highly tissue and cell type-specific gene regulation. In case of the highly regulated 
tenascin-C and TNW, however, more and more evidence suggests that these two proteins are 
important regulators of cell division, migration and differentiation in adult stem cell niches (20) as 
well as in cancer (132). Moreover, because of their very localized and high expression in the 
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extracellular matrix, both tenascin-C and TNR are very well suited for targeting antibodies and 
drugs to certain types of tumors (133). For this therapeutic approach to work effectively, it is 
important to know how tenascin-C or TNW gene expression is affected e.g. by cytotoxic drugs in 
combined therapy, and what signaling pathways are involved. From a basic research point of 
view, the tenascin family provides an intriguing example for a vertebrate protein family of 
paralogues with similar structure and function, but with distinct expression patterns in space and 
time that are generated by different mechanisms of regulation of the respective genes. 
 






Figure 1: Schematic representation of the transcription start sites and the first exons of the four 
human tenascin genes. TNC, tenascin-C, TNN, tenascin-W; TNR, tenascin-R; TNXB; tenascin-
X. Note that the very large first introns are not drawn to scale (indicated by dotted lines); their 
length differs in the four genes. Note also that the TNC and TNN genes possess TATA boxes 
whereas the TNR and the TNXB genes do not. In contrast to TNC, TNN and TNR that have a 
single transcription start site (TSS1), the TNXB gene has three (TSS1, TSS2, TSS3), and it 
features several noncoding exons that are differentially spliced. 





Table 1: External signals, signaling pathways and transcription factors involved in the regulation 
of the four tenascin genes. TNC, tenascin-C; TNR, tenascin-R, TNXB, tenascin-X; TNN, 
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II.4  Aim of the work 
It is well known that two of the four tenascin family members are significantly regulated by the 
tissue microenvironment: tenascin-C and tenascin-W (110). While a lot is known about tenascin-
C, its regulation and gene structure, no information about these aspects of tenascin-W have 
been reported. In this work, the primary goals were to investigate the gene structure of tenascin-
W and to explore its role and regulation in the bone metastatic niche of breast cancer. As 
catalyst for the exploration of the so far undefined tenascin-W gene structure and regulation, we 
performed computational as well as experimental analysis of the tenascin-W gene locus to 
identify the transcription start site(s), the promoter and its transcription factor binding sites as 
well as potential regulatory regions in the first intron. Since tenascin-W is known to be 
expressed in breast cancer stroma (105) and 80% of women with advanced breast cancer have 
bone metastases (111) we decided to investigate a potential role of tenascin-W in the metastatic 
spreading of breast cancer cells to bone.  
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What`s new? 
This is the first report describing a function for tenascin-W in metastasis as well as the first 
report on tenascin-W gene structure and transcriptional regulation by TGF-beta and 
glucocorticoids in human bone marrow stromal cells. Our results support a role for TNW as a 
niche component for breast cancer metastasis to bone by supporting cell migration and cell  
proliferation of the cancer cells.





Tenascin-W is a matricellular protein with a dynamically changing expression pattern in 
development and disease. In adults, tenascin-W is mostly restricted to stem cell niches, and is 
also expressed in the stroma of solid cancers. Here we analyzed tenascin-W expression in the 
bone microenvironment of breast cancer metastasis. Osteoblasts were isolated from tumor-free or 
tumor-bearing bones of mice injected with MDA-MB231-1833 breast cancer cells. We found a 
4-fold upregulation of tenascin-W in the osteoblast population of tumor-bearing mice compared 
to healthy mice, indicating that tenascin-W is supplied by the bone metastatic niche. Transwell 
and co-culture studies showed that human bone marrow stromal cells express tenascin-W protein 
after exposure to factors secreted by MDA-MB231-1833 breast cancer cells. To study tenascin-
W gene regulation, we identified and analyzed the tenascin-W promoter as well as three 
evolutionary conserved regions in the first intron. 5’RACE analysis of mRNA from human 
breast cancer, glioblastoma, and bone tissue showed a single tenascin-W transcript with a 
transcription start site at a non-coding first exon followed by exon 2 containing the ATG 
translation start. Site-directed mutagenesis of a SMAD4 binding element in proximity of the 
TATA box strongly impaired promoter activity. TGFβ1 induces tenascin-W expression in human 
bone marrow stromal cells through activation of the TGFβ1 receptor ALK5, while 
glucocorticoids are inhibitory. Our experiments show that tenascin-W acts as a niche component 










Despite great progress in the treatment of breast cancer, metastatic disease is not curable and the 
treatment options remain palliative. Bone is the most frequent site of metastatic lesions and 
occurs in 80% of women with advanced breast cancer.
1,2
 Therefore, it is important to investigate 
the mechanism for this osteotropism as well as the interactions of the cancer cells with the bone 
microenvironment with the ultimate aim being to define new treatment options. The 
microenvironment, including the extracellular matrix (ECM) surrounding primary tumors as well 
as metastases, has been found to be an important factor determining tumor cell behavior.
3-6 
Tenascin-C (TNC) and tenascin-W (TNW) are two ECM proteins that are highly expressed in 
the stroma of most solid tumors 
7,8
 and a crucial role for TNC in breast cancer metastasis to the 
lung has been demonstrated.
9,10
 Currently there is no information on TNW expression or a 
potential role in breast cancer metastasis, the goal of the work described here. 
Prominent expression of TNW has been reported in developing bone where it was shown to be 
particularly abundant in the stem cell niche of the cambium, the location of osteoblast 
progenitors 
11
. Therefore, we decided to investigate TNW expression in the bone environment in 
the MDA-MB231 xenograft model of breast cancer metastasis.
12
  We used MDA-MB231-1833 
cells which have bone tropism following intracardial injection.
12
 We found that MDA-MB231-
1833 tumors induced TNW in situ in the bone stroma. Moreover, in a coculture model of MDA-
MB231-1833 cells with human bone marrow derived stromal cells (BMSCs), we also observed 
increased levels of TNW. To provide mechanistic insight to this observation, we investigated the 
signaling pathways inducing TNW in BMSCs and characterized the gene structure of the human 
TNW gene. We identified a crucial effect of TGF-beta signaling in the regulation of TNW 
expression in human BMSCs which in turn will provide a congenial microenvironment for tumor  
cell growth.
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Material and Methods 
 
Bone metastasis model 
The breast cancer cell line MDA-MB231-SCP1833 was kindly provided by Prof. J. Massagué 
(Memorial Sloan Kettering Cancer Center, New York). These cells were transduced with a 
lentiviral vector encoding Luc-2eGFP genes (L2G) as described in.
13
 MDA-MB231-SCP1833 
L2G cells were harvested from subconfluent cell culture plates, washed in PBS and injected into 
the left ventricle (0.5x10
6
 in 100ul PBS) of 8-week old female NOD SCID mice. Successful 
injections were verified by the pumping of arterial blood into the syringe and imaging with a 
bioluminescence imager (Berthold technologies, NightOwl). Bone marrow metastases were 
monitored by in vivo imaging over 20 days after which long bones were excised for cell sorting 
or immunostaining. 
Bone marrow cell suspensions from tumor free or tumor bearing mice (n=6-10 samples) were 
obtained by grinding the bone with mortar and pestle and digestion of the bone powder for 1h at 
37ºC with 1mg/ml collagenase (Roche), 1mg/ml dispase (Roche) and 50KU/ml DNAse (Sigma) 
into a single cell suspension. Stromal cells and hematopoietic fractions were enriched via a 
discontinuous percoll density gradient separation using 1.065g/L and 1.115g/L (GE Healthcare). 
Remaining red blood cells were lysed (140mM NH4Cl and 17mM Tris-base, pH7.4) and cells 
were stained and sorted directly into RNA extraction buffer (Qiagen) using a MoFlo cell sorter 










cells. RNA was extracted with Pico Pure RNA Isolation Kit (Arcturus cat.KIT0204) and cDNA 
prepared with the Ovation Pico Kit (NuGen cat.3302) following standard procedures and used 
for Real-Time Quantitative PCR (qRT-PCR, see below). 
  
Cell Culture 
Fibrosarcoma HT1080 cells (CCL-121, ATCC) and MDA-MB231-SCP1833 cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) and 10% fetal bovine serum (FBS). Human 
bone marrow stromal cells (BMSCs) immortalized with the hTERT/GFP system were kindly 
provided by Dr. A. Scherberich (University Hospital of Basel).
14
 BMSCs were cultured in 
Eagle’s Minimal Essential Medium Alpha (α-MEM) with 2mM L-glutamine and 10% FBS. To 
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strip glucocorticoids from serum, 2.5g of dextran-coated charcoal (DCC; Sigma-Aldrich) was 
added to 125ml of serum and mixed gently overnight at 4
o
C. DCC was removed by 
centrifugation followed by sterile filtration.  
 For co-culture assays 3x10
3
 BMSCs and 6x10
 3
 MDA-MB231-SCP1833 cells were 
seeded per 1cm
2
 into poly-L-lysine coated 8-well chamber slides (BD Falcon). In parallel each 




. For transwell co-culture 
assays, cells were cultured in wells containing inserts separated by a polycarbonate membrane 
with 0.4 µm pores (Costar). MDA-MB231-SCP1833 or BMSCs cells were plated in the upper 
chamber (5x10
3 
cells in 0.5ml medium)  and BMSCs or MDA-MB231-SCP1833 (5x10
4 
cells in 
1.5ml) were cultured on 10mm round glass coverslips coated with fibronectin (5ug/ml, for 1h) 
placed in the bottom chamber. Cells were cultured in α-MEM/10% FBS and maintained for 7 
days with medium changes every 2 days.  
 
Immunostaining 
Long bones were fixed for 48h in 10% formalin, decalcified in 0.5M  EDTA (pH7.5) for 3 days 
at 4°C, dehydrated in 30% sucrose in PBS overnight and embedded in OCT. Antigen retrieval of 
8µm sections was performed in citrate buffer 10mM pH6, 0.5% Tween20 (2 hours) followed by 
blocking with 3%BSA/0.2%Triton in PBS. Cultured cells were fixed with 4% formaldehyde in 
PBS for 15min at RT, permeabilized in cold 100% methanol for 2min at -20
o
, washed twice with 
PBS and blocked with 0.01% Tween/1% BSA in PBS. Slides with bone sections or cells were 
stained with rabbit-anti-mTNW 
11
 and the mouse monoclonal anti-hTNW56O 
15
 followed by 
secondary antibodies Alexa Fluor 568 (Invitrogen). Slides were mounted with ProLong Gold 
containing DAPI (Invitrogen) and images acquired using an Axio Imager Z2 LSM700 confocal 
microscope (Zeiss). 
  
RNA Isolation and Real-Time Quantitative PCR  
Total RNA was isolated from BMSCs treated with 5ng/ml TGFβ1 (R&D Systems), in α-
MEM/0% FBS for 24h, with or without 10µM SB-431542 inhibitor (Sigma) added to the cell 
cultures 1h before the addition of TGFβ1. Total RNA was extracted from BMSCs using RNeasy 
Mini Kits and QIAshredder (Qiagen). RNA was transcribed into cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies/Applied Biosystems) and qRT-PCR 
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analysis was performed with SYBR green PCR SuperMix-UDG/ROX (Invitrogen). The level of 
expressed genes was measured by Relative quantification (Ct method) or Relative Standard 
Curve quantification. Human TBP and mouse GAPDH genes were used as internal reference. 
Primers used are listed in additional supporting information file 1. 
 
Cell proliferation and migration assays 
TNW protein was purified as described.
11
 For proliferation assays the 5-bromo-2-deoxyuridine 
(BrdU) chemiluminescent enzyme incorporation kit was used (Roche). Tumor cells were seeded 
in a 96-well black plate at a density of 1x10
4
 per well and incubated overnight. After the addition 
of different concentrations of TNW protein (0-10µg/ml) in serum-free DMEM cell proliferation 
was quantified 48h after plating and the addition of 10µM BrdU for 2h at 37
o
C. Cells were fixed 
and stained and the incorporated BrdU detected in a chemiluminescence microplate reader 
(Perkin Elmer). 
 Cell migration assays were performed using 24 transwell chambers (8 µm pore size; 
Costar). The underside of the polycarbonate membrane was pre-coated with different 
concentrations of TNW recombinant protein (0-10µg/ml) for 2h at 37
o
C and subsequently 
blocked for 30min at 37
o
C with 1% BSA/PBS. MDA-MB231-SCP1833 cells were cultured in 
the upper chamber in serum-free DMEM (1x10
5
 cells in 1ml). Serum-free medium was added to 
the bottom chamber (0.6ml) and cells were allowed to migrate for 24h. Cells were scraped off 
the top of the membrane using cotton swabs. Cells that had migrated across the membrane were 
fixed in 4% formaldehyde and stained with 1% crystal violet and total cell-covered areas were 




Transcription Start Site Identification and cloning of the reporter constructs 
5’RACE was performed using total RNA from normal bone (OriGene), breast cancer tissue 
(Clontech) and glioblastoma (OriGene) using the 5’/3’ RACE Kit, (2nd Generation, Roche). 
Briefly, 1µg of total RNA was reverse-transcribed into first-strand cDNA using the human 
tenascin-W specific primer hSP1. To identify the 5’ end of the TNW mRNA two gene specific 
primers hSP2 and hSP3 were used (primers are listed in additional supporting information file 1). 
DNA products were cloned and sequenced.   
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Different promoter constructs, all containing exon 1 (77bp) preceded by different lengths of 
human tenascin-W promoter sequences were amplified from human genomic DNA isolated from 
HEK293 cells resulting in the following constructs: pSEAP-TNW (-1800bp), pSEAP-TNW (-
957bp), pSEAP-TNW (-512bp), pSEAP-TNW (-320bp), pSEAP-TNW (-252bp), pSEAP-TNW 
(-148bp), pSEAP-TNW (-79bp), pSEAP-TNW (-59bp), pSEAP-TNW (-35bp), and pSEAP-
TNW (+77bp). See additional supporting information file 1 for the list of primers used. The 
primers included NheI and XhoI restriction sites for directional cloning into the MCS of 
pSEAP2-basic (Clontech). The three conserved intronic DNA fragments were amplified from 
HEK293 genomic DNA as template and inserted into NheI/HindIII sites of the pSEAP-basic 
vector. Further deletions of the second conserved region were created. All primers used and their 
intronic locations are listed in additional supporting information file 1. The three intronic regions 
were also cloned into the NheI and MluI sites 5´ of pSEAP-TNW (-79bp) creating the plasmids 
pSEAPI/-79, pSEAPII/-79 and pSEAPIII/-79.  
 Site-directed mutagenesis of the SMAD4 binding site (gcctAGACagg) was performed 
using a scrambled sequence (AGAGTGATCA), which does not display any known cis-acting 
sequence. Overlapping primers used for PCR including the scrambled sequences underlined are 
listed in additional supporting information file 1. Following transformation of the DpnI-digested 
PCR, plasmid DNA was isolated and the mutations confirmed by sequencing. 
 
Cell transfection and reporter gene assays 
HT1080 cells were cultured in DMEM/10% FCS. For reporter assays cells were plated at 5x10
4
 
cells/well in 12-well plates overnight to reach 60-70% confluence. Cells were transfected by 
jetPEI (Polyplus) with 0.6µg/well of total DNA (pSEAP reporter construct and pMetLuc for 
normalization mixed at 1:20 molar ratio) in DMEM/0.3% FCS. Reporter activity was measured 
24h after transfection. Alternatively, cells were transiently transfected in 3% FBS or 3% DCC 
treated FBS for 24h. Secreted alkaline phosphatase (SEAP) activity in the culture medium was 
determined using the SEAP Reporter Gene Assay Kit (Roche) and for normalization the Ready-
To-Glow secreted luciferase reporter system (Clontech) and measured in a luminometer (Mithras 
LB940; Berthold technologies). SEAP values were normalized to Luciferase values to control for 
transfection efficiency. The normalized luminescence values were then standardized by the 
background activity (empty vector). The pSEAP-TNW-79bp construct was included in all 
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experiments and was used to calibrate different experiments. Error bars represent the standard 
error of the mean (SEM) between all replicates of each experiment.   
 
Statistical Analyses 
Data are represented as means and SD or SEM as stated in the figure legends. Statistical analysis 
using a two-tailed t-test was carried out with SigmaPlot for Windows version 12.0. All the 
experiments shown are the means of 3 replicates. The difference between two groups was 
statistically significant when P<0.05. 
In silico analyses  
The genomic location of the human tenascin-W gene and its evolutionary conservation was 
examined using the UCSC genome browser (http://genome.ucsc.edu/). MatInspector 
(http://www.genomatix.de) was used to identify predicted transcription factor binding sites in the 
genomic sequences. 




Tenascin-W is induced in bone metastases of MDA-MB231-1833 breast cancer cells 
We investigated the expression of TNW in the bone stroma of MDA-MB-231-SCP1883 tumor-
bearing mice. Osteoblasts were isolated from tumor-free or tumor-bearing bones as described in 
Materials and Methods and RNA was extracted from this host cell population. Using quantitative 
real time PCR (qRT-PCR) mouse TNW mRNA levels were up-regulated 4-5 fold in osteoblasts 
isolated from bones harboring metastases compared with osteoblasts from non-tumor-bearing 
control bone (Fig.1A). Immunostaining of the long bones shows that TNW is expressed in the 
region surrounding the GFP-expressing tumor cells (Fig.1B). Using species-specific monoclonal 
antibodies, we verified that TNW is specifically unregulated in the host tissue since no human 
TNW was detectable. Thus, the MDA-MB231-1833 cells are not a source of TNW, but are 
surrounded by a host-derived TNW-rich extracellular matrix in the bone metastatic niche. 
 
Breast cancer cells release factors that induce tenascin-W expression in human bone 
marrow stromal cells  
Prompted by the striking correlation of TNW expression with breast cancer metastases, co-
culture assays were established to investigate whether paracrine interaction between MDA-
MB231-1833 and immortalized human BMSCs can induce TNW expression. Indeed, BMSCs 
are targets of homing signals and they represent a significant cellular source not only of 
osteoblasts but also of myofibroblasts within the tumor stroma supporting tumor cells.
17 
Monocultures and co-cultures of the two cell lines were subjected to immunofluorescence 
staining to detect TNW protein expression. Interestingly, TNW was exclusively detectable in co-
culture conditions and neither the tumor cells nor the BMSCs alone yielded any TNW staining 
(Fig.1C).  
 In order to examine whether the expression of TNW in co-cultures depends on direct cell-
cell contacts, transwell co-culture assays were performed (Fig.2). Each cell type was cultured in 
the bottom well of transwell culture dishes (Fig.2A), either alone or with the other cell type 
cultured in an upper well (Fig.2B). Upper and lower compartments were separated by a 
polycarbonate membrane with 0.4 µm pores, to allow the diffusion of soluble factors, but not the 
transmigration of cells (Fig.2B). For each condition, the cells in the bottom well were analyzed 
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by immunostaining for TNW expression after 7days in culture. This confirmed that neither cell 
type alone produced TNW, but TNW was induced in BMSCs in the presence of tumor cells in 
the upper chamber and not vice versa. Thus, in this in vitro system, tumor cells can induce the 
expression of TNW in the bone-derived BMSCs and this depends on the release of a soluble 
factor (or factors) secreted by the tumor cells.   
 
Transcriptional regulation of tenascin-W gene expression 
To get a hint on the possible factor and signaling pathway inducing TNW expression in BMSCs, 
we decided to isolate and study the TNW gene promoter and to identify regulatory sequences 
present in the TNW gene. In the case of human TNW, the gene name in the databases is TNN. 
The 5`part of the TNN gene, as it is annotated in the UCSC browser, is shown in Fig.3A. It 
shows a first non-coding exon separated by a large intron from exon 2, which contains the ATG 
translation start. Underneath the sequence tracks, the evolutionary conservation reveals high 
conservation of the exon sequences and the putative promoter region as well as of three 
conserved regions in the first intron (Fig.3A). To experimentally confirm the predicted 
transcription start site (TSS) we performed 5’RACE experiments (Fig.3C). To assess potential 
transcript variants in different tissues that are known to express TNW, we used total RNA 
isolated from glioblastoma and breast cancer tissues which have high TNW expression levels 
15,18
 as well as RNA from healthy bone tissue, since TNW is known to be associated with the 
osteogenesis process.
19 
PCR products were cloned and sequenced. From all RNA sources tested, 
we found a single TNW transcript with a TSS at the non-coding first exon. Thus, normal and 
cancer tissues tested here are using a common single TSS to initiate TNW transcription.  
 In order to identify regulatory regions present in the TNW promoter, promoterless SEAP 
(secreted embryonic alkaline phosphatase) reporter constructs containing exon 1 (+77) and 
different parts of the 5' flanking region up to a length of 2kb were cloned (Fig.3B). Reporter gene 
activity was examined using the human fibrosarcoma cell line HT1080. Transfection of the 
promoter constructs revealed that the main control region was contained within -512bp of the 
TSS since longer constructs gave similar results. Thus, the promoter region coincides with the 
UCSC Genome browser tracks ESPERR Regulatory Potential (Fig.3B; light blue) and the 
Vertebrate Multiple sequence Alignment & Conservation tracks (Fig.3B; dark blue). However, 
further shortening of the promoter constructs to -320, -252 and -148bp revealed a gradual loss of 
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reporter activity. This could be related to the loss of binding sites for factors that enhance the 
promoter activity in a cooperative manner. One such factor could be SMAD1/5, since by 
MatInspector analysis a GC-rich Smad-binding element (SBE) was detected at position -230. An 
increase of reporter activity was observed by the deletion of the sequence from -148 to -79, 
pointing to the presence of a negative regulatory site in this region. Using MatInspector, a 
GATA-binding element was detected in this region and may be responsible for the repression in 
a similar way as it was described for TNC.
20
  Interestingly, the short -79bp minimal promoter 
exhibited the highest activity after transient transfection which was lost by the deletion of -79 to -
59bp, indicating important transcription factor binding sites within these 20bp. Indeed, 
MatInspector analysis revealed a SMAD4 site at this location. The sequence of the TNW 
promoter and the first exon as well as potential transcription factor binding sites are given in 
additional supporting information file 2. 
 
Analysis of the evolutionary conserved regions within the first intron. 
 Further inspection of the TNN genomic locus using the UCSC genome browser revealed 
striking patterns of histone modifications within the first intron of the TNN gene, namely an 
H3K4me1 enhancer chromatin signature, as well as H3K27 acetylation that defines nucleosome 
exclusion regions (Fig.4A). These epigenetic marks overlap with three evolutionarily conserved 
regions which we tested for a potential involvement in the regulation of TNW transcription 
(Fig.4B). We cloned the three intronic conserved modules I, II and III upstream of the SEAP 
reporter gene and tested their effects on reporter gene activity. While the first conserved region 
(+1178/+1909) appeared to act as a silencer, the second conserved region (+2920/+3447) 
strongly enhanced transcription when compared to the pSEAP basic vector. The third region did 
not seem to influence the reporter gene activity when tested on its own, but in conjunction with 
the active region II, both, region I as well as III seemed to silence the activity of region II 
(Fig.4B). Further dissection of the second conserved region showed that the sequence between 
+3299 and +3447 was mainly responsible for the strong activation (Fig.4B). Although we did not 
find any alternative TSS in the tissues analyzed, the possibility remains that this region might be 
an alternative promoter of the TNN gene. 
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Identification of negative and positive trans-acting elements in the TNW gene 
After the experimental determination of the most important regions of the TNW gene affecting 
promoter activity, we experimentally tested the identified putative transcription factor binding 
sites within the promoter and first intron regions. Computational predictions showed the 
presence of a SMAD4 nuclear transcription factor binding site at -61bp from the TSS, next to a 
TATA box sequence located at -54bp upstream of exon 1. This SMAD4 binding site 
(gcctAGACagg) is located within the 20bp region found to be crucial for the high activity of the 
proximal TNW promoter. To test whether this binding site is responsible for the promoter 
activity, site-directed mutagenesis of the SMAD4 element was performed (Fig.5A). Indeed, the 
presence of the scrambled sequence (AGAGTGATCA) strongly impaired the SEAP reporter 
gene expression driven by the minimal basal promoter (-79bp). SMAD4 is an intracellular 
mediator of the TGF-β signaling pathway.21 Therefore, we assessed whether TGF-β1 acts on 
endogenous TNW gene expression in BMSCs (Fig.5B). To examine the specificity of action of 
TGF-β1 on TNW gene transcription we evaluated the efficiency of SB-431542, a selective 
inhibitor of the TGF-β1 receptor/ALK5, to inhibit TNW induction (Fig.5B). Preincubation of 
BMSCs with the ALK5 inhibitor abolished induction of TNW transcripts as assessed by qRT-
PCR. Thus, we identified TGF-β1 as a factor inducing human TNW gene expression in BMSCs 
through activation of ALK5. A similar result was obtained using conditioned medium of MDA-
MB231-1833 instead of TGF-β1, which also led to an ALK5-dependent incease of TNW 
transcripts in BMSCs, confirming that TGF-β1 is one of the MDA-MB231-1833 secreted factors 
inducing TNW (Additional supporting information file 3). 
 Further sequence analysis of the intron showed a negative glucocorticoid response 
element (nGRE: tttttccaGGAGaga) located in the first conserved region. This prompted us to 
investigate whether or not glucocorticoids have an inhibitory effect on TNW transcription. For 
this purpose, we stripped endogenous steroids from the serum by using dextran-coated charcoal 
(DCC-FBS). Conserved intronic regions were cloned upstream of the  -79bp proximal promoter 
construct and transfected into HT1080 cells in the presence of 3% untreated FBS or DCC-FBS 
for 24h (Fig.5C). Indeed the first intronic module (I./-79bp) containing the nGRE exerted 
transcriptional repression of the TNW promoter measured by a 2-fold lower activity in the cells 
grown in untreated versus steroid-stripped FBS. This was confirmed in BMSCs. In the presence 
of glucocorticoid-depleted FBS, BMSCs showed higher TNW transcript levels than in normal 
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FBS (Fig.5D). A model representing the main regulatory elements of the promoter and first 
intron of the TNW gene analyzed here is shown in Fig.5E. 
 
Tenascin-W promotes breast cancer cell migration and proliferation in vitro 
Since the metastatic tumor cells in vivo are surrounded by TNW we investigated a potential 
functional role of TNW in tumor progression, MDA-MB231-1833 cells were treated with 
different concentrations of human TNW recombinant protein (5-10µg/ml) and analyzed for 
proliferation and migration. There was a 3.5-fold increase in BrdU incorporation in MDA-
MB231-1833 cells measured in the presence of TNW 48h after starting the cultures (Fig.6A). 
Cell migration was assessed using transwell chamber assays. The underside of the filters was 
coated with TNW to investigate its role as chemoattractant. There was a 3.5-fold increase in 
MDA-MB231-1833 cell migration towards TNW compared to control filters indicating a pro-
migratory function of TNW for the MDA-MB231-1833 cells (Fig.6B). 
 





It is well known that paracrine signals released by breast cancer cells orchestrate the fate of 
stromal cells residing in the tumor microenvironment and vice versa.
4,22,23
 Stromal cells are 
targeted by tumor-released factors and in response undergo myofibroblast-like differentiation to 
a so-called cancer associated fibroblast.
24
 We propose that breast cancer cells, after homing to 
the bone marrow via blood circulation, secrete TGFβ1 which induces changes in the bone 
marrow niche, including the deposition of TNW in the extracellular matrix. Exposure of MDA-
MB231-1833 cells to TNW supports their migration and proliferation establishing a “vicious 
cycle” for cancer progression by promoting the growth and further invasive behavior of the 
breast cancer metastases (Fig.6C). We showed that a crucial signaling pathway for the induction 
of TNW is the TGFβ1 secreted by the tumor cells which induces Smad4-dependent transcription 
of the TNW gene in the bone marrow stromal cells. Indeed, TGFβ1 has been found to be a major 
osteolytic factor secreted by MDA-MB231 cells.
25
 Furthermore, downregulation of Smad4 in 
MDA-MB-231 cells strongly inhibited bone metastasis formation. 
26
 In contrast to the induction 
of TNW expression by TGFβ1, we found that glucocorticoids have a negative impact on TNW 
expression. A similar antagonistic effect has also been described for the regulation of the TNW 
family member TNC and TNX.
27,28
 Interestingly, anti-inflammatory agents, including 
corticosteroids, are in use as cancer therapy.
29
 It is likely that such treatments also affect the 
ECM composition of the cancer microenvironment.  
The actual situation in vivo is of course more complicated and it is clear that also osteoclasts are 
involved in the metastatic process.
30,31
 It is known that upon stimulation of osteoblasts by 
cytokines released by the tumor cells, osteoblasts release RANKL which in turn promotes 
differentiation and activation of osteoclasts. Activated osteoclasts resorb the bone matrix with 
the consequent release of cytokines including TGFβ.32 These cytokines will act back on the 
osteoblasts as well as the tumor cells and in a vicious cycle keep the osteolytic lesions growing. 
Because of these findings, inhibition of osteoclasts by bisphosphonates as well as RANKL and 
TGFβ-targeting agents are presently tested as adjuvant therapy for the treatment of breast cancer 
patients with bone metastases.
32-36
 The benefit of such treatments may include reduced TNW 
expression in the microenvironment of the metastatic cells and alleviate the tumor-promoting 
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effects exerted by TNW. Tumor-promoting effects of TNW may include promotion of growth 
and migration as well as pro-angiogenic effects, since TNW was found to be expressed around 
tumor blood vessels in several types of cancers and to stimulate endothelial sprouting in 
culture.
8,18
 Furthermore, with its tumor and metastasis-specific expression, TNW may itself be a 
target for antibody-mediated drug targeting of the bone metastatic niche. 
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Figure 1. TNW is upregulated in bone metastasis of breast cancer.  
A, TNW transcript levels in RNA isolated from osteoblasts sorted from two individual tumor-
free (1, 2, black) or two tumor-bearing mice (3, 4, red). Averages ± s.d. of two independent 
experiments in triplicate are shown. B, tissue sections of tibia show GFP-MDA-MB231-1833 
metastases (green). Staining of TNW was detectable with anti-mouse TNW only (red, mTNW, 
left panel) but not with anti-human TNW (hTNW, right panel). Scale bar, 100µm. C, 
immunofluorescence staining for TNW of human bone marrow stromal cells (GFP-BMSCs) and 
human breast cancer cells (GFP-MDA-MB231- 1833) cultured alone, or in co-culture reveals 
TNW protein (red) expression after 7 days of co-culture. Nuclei were labeled with DAPI (blue). 
Scale bars, 50µm.  
 
Figure 2. Soluble factors secreted by MDA-MB231-1833 breast cancer cells stimulate TNW 
expression in BMSCs.  
A, monocultures of GFP-BMSCs (left panels) and GFP-MDA-MB231-1833 cells (right panels) 
maintained for 7 days in culture. Nuclei were stained with DAPI (blue). Staining with human 
anti-TNW monoclonal antibody does not detect any TNW expression. B, MDA-MB231-1833 
cells or BMSCs were seeded in the bottom well of transwell chambers (MDA-MB231-1833 
lower; BMSCs lower) and exposed to the other cell type in the upper chamber in an indirect co-
culture system. Under these conditions TNW protein expression (red) was detected exclusively 
in BMSCs and not in MDA-MB231-1833 cells Scale bars, 100µm for all panels except for the 
magnification shown in the right panels representing 20 µm.  
 
Figure 3. Experimental and computational analyses of the transcription start site and 
promoter activity of the TNW gene.   
A, graphical representation of the two first exons of the TNW gene (marked in blue rectangles) 
using the UCSC Genome Browser. In addition to sequence conservation of the exons and 
promoter region, three regions of conservation among the vertebrate genomes are observed 
within the first intron. B, to characterize the TNW promoter, exon-1 (+ 77bp) and different 
lengths of the 5’ flanking region as indicated were cloned upstream a promoterless SEAP vector. 
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The UCSC Genome browser tracks ESPERR Regulatory Potential (7 species; light blue) and 
Vertebrate Multiple sequence Alignment & Conservation (17 species; dark blue) of about 500bp 
upstream of the TSS are depicted above the promoter constructs. Plasmid DNA constructs were 
transiently transfected in HT1080 cells for 24 hours. SEAP activity is normalized to a co-
transfected secreted luciferase plasmid and plotted relative to the promoterless SEAP vector 
control. Values are the average and SEM of three independent experiments. c, agarose gel 
electrophoresis shows the products resulting from 5’RACE of total RNA from breast cancer, 
healthy bone and glioma tissues as indicated. Cloning of the DNA bands (400bp) and the 
subsequent sequencing revealed a single transcription start site adding a 79bp first exon to exon 
2 containing the ATG start codon. 
 
Figure 4.  Analysis of the evolutionary conserved regions within the first intron.  
A, Multiple alignment of conserved genomic sequences using the UCSC Genome Browser is 
visualized in green lines and shows the conservation to human TNW from top to bottom of  
Rhesus, Mouse, Dog, Horse, Armadillo, Opossum, Platypus, Lizard, Chicken, X_tropicalis, and 
Stickleback orthologs. Chromatin signatures shown on top (H3K4Me3, H3K4Me1 and, 
H3K27Ac) overlap with the intronic modules. B, in order to assess  potential transcriptional 
activities, each conserved region I, II and III, combinations thereof and truncated versions as 
indicated were cloned upstream of the SEAP reporter gene. Transient transfections of the 
constructs in HT1080 cells were analyzed for SEAP activity as described in Fig.3B. The 
experiment was performed in triplicates and repeated three times (error bars = SEM). 
 
Figure 5. Regulation of TNW transcription by TGFβ1 and glucocorticoids.  
A, The Smad4 binding site (gcctAGACagg) was mutated by site-directed mutagenesis and 
replaced with the scrambled sequence (Scr- AGAGTGAT). Construct -79/+77 containing the 
normal (SMAD4) or modified Smad4 sequence (Scr-control) was transfected in HT1080 cells 
and analyzed for SEAP activity in comparison to the empty pSEAP as described in Fig.3B. B, 
BMSCs were treated with SB-431542-DMSO (10µM) or DMSO only for 1h before the addition 
of TGFβ1 (5 ng/ml) for 24h. TNW transcript levels were then analyzed by qRT-PCR. C, 
Constructs with the three intronic regions (I./II./III.) cloned upstream the minimal TNW 
promoter (-79bp/+77) were transfected in HT1080 cells in medium containing 3% FBS (light 
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green bars) or glucocorticoid-depleted 3% DCC-FBS (dark green bars) for 24h. SEAP activity 
was analyzed as in Fig. 3 revealing that the intronic conserved region I inhibited the reporter 
activity in a glucocorticoid-dependent manner. D, BMSCs were cultured in untreated 3% FCS 
(light green bar) or in the presence of 3% charcoal/dextran treated FBS for 24h before measuring 
transcript levels of TNW by qRT-PCR. All experiments were repeated at least three times (error 
bars = SEM). E, Schematic model of the TNW gene regulation by a SMAD4 element preceding 
a TATA box in the proximal promoter region upstream of exon 1 (red box 1) and a negative 
glucocorticoid-response element (nGRE) in the first conserved region within the first intron 
(green oval I).  
 
Figure 6. Effect of TNW on breast cancer cell proliferation and migration.  
A, MDA-MB231-1833 cells were treated with different concentrations of recombinant human 
TNW protein (5-10 µg/ml) in serum-free medium. Proliferation was measured by BrdU 
incorporation 48h after exposure to TNW. B, MDA-MB231-1833 cells were seeded in the upper 
chambers of transwell migration dishes and allowed to migrate for 24 h towards TNW coated on 
the underside of the filters. Cells on the bottom side of the filters were stained and photographed 
(scale bar = 50 µm) and the cell-covered area was quantified (error bars = SD). Statistical 
analysis was assessed by paired Student’s t-test. P values <0.05 are considered statistically 
significant. C, Model for the role of TNW in breast cancer metastasis to bone: After extravasion 
and homing to the bone MDA-MBA231 cells are releasing TGFβ1 which triggers BMSCs to 
differentiate into TNW secreting cancer associated fibroblasts (CAFs). TNW in turn is able to 







90  III. Results 
 
 
Additional supporting Information 
 
Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic 








, Nancy E. Hynes
1,2






Additional file 1. Primer list 
 
Additional file 2. Promoter sequence and 5´end of the TNW gene. 
 
Additional file 3. Induction of TNW by MDA-MB231-1833 conditioned medium. 








Supplemental Figure 1 
Promoter sequence and 5´end of the TNW gene. The start of each promoter construct is designated 
above the sequence with the first bp in bold. The TSS is marked with +1 followed by the sequence of the 
first non-coding exon and the sequence of the second exon up to the translation start codon ATG in 
italic. The main transcription factor binding sites addressed in this paper are underlined (core sequences 
double underlined) and labeled above the sequence when present on the + strand and below, when 
present on the – strand. 
 





Supplemental Figure 2  
Induction of TNW by MDA-MB231-1833 conditioned medium. (A) BMSC cells were seeded at a density 
of 1 x 105 in 6 well plates overnight at 37oC to reach 70% confluence. After washing with PBS they were 
maintained in α-MEM serum free with or without the addition of 10 µM SB-431542 inhibitor for 1h 
(Sigma). Following SB-431542 treatment, cells were exposed to conditioned medium (conditioning time 
48h) from MDA-MB231-1833 cells mixed in a ratio of 1:1 with fresh serum-free medium plus 0.2% BSA. 
Total RNA was extracted from BMSCs after 24h using and transcribed into cDNA. Samples were 
subjected to real time PCR analysis with human TBP as internal reference. (B) MDA-MB231-1833 cells 
were maintained for 24h in DMEM supplemented with 10% FBS and total RNA was isolated. RT-PCR 
reactions were analyzed by agarose gel electrophoresis to reveal the presence of TGF1 (336bp), IL-8 
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III. 2 Unpublished Results 
III. 2. 1 An intronic positive transcription regulatory element 
The high gene expression achieved by transfecting HT1080 cells with pSEAP vector containing 
the second conserved (+3299/+3447) region within the first intron (cf. Fig.4 of the manuscript 
Chiovaro et al., submitted), prompted us to investigate more closely the identity of this 
sequence. It is well known that the activity of enhancers is generally insensitive to the 
orientation and location, whereas changes in promoter position and orientation greatly impair its 
function (112). Therefore, cloning of the fragment (+3299/+3447) in opposite direction was 
carried out (Fig.III.1). The alteration in orientation was found to cause a strong decrease in 
SEAP gene expression. This suggested to us the presence of a second promoter in this region.  
 
Figure III. 1: Graphical representation of the fragment (+3299/+3447) within the second conserved intronic region 
visualized by using the UCSC Genome Browser. Vertebrate Multiple sequence Alignment and Conservation for 
instance for human and mouse is indicated by green lines. The region (+3299/+3447) was cloned in opposite 
            (3’-5’)              m                  S A                (      ). S A        ty of the TNW intronic 
constructs in HT1080 cells was compared to the negative control (pSEAPbasic). Experiment was performed in 
triplicates and repeated three times (error bars = SEM). 
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Most promoters harbor control elements for expression across a wide range of cell and tissue 
samples leading to a precise pattern of gene expression (113). However, another mechanism 
for tissue-specific gene regulation is the acquisition of alternative promoters for a single gene 
each leading to distinct tissue-specific expression (114) Although findings from our studies 
showed only one single tenascin-W transcript form generated by a TSS located upstream of the 
non-coding exon 1 in breast cancer, glioblastoma and bone tissues (Chiovaro et al., 2014), we 
cannot exclude the potential existence of an alternative tenascin-W promoter used in a different 
context. Recent reports have shown how enhancer sequences can act as alternative promoters 
to contribute to divergent transcription in an orientation-dependent manner (115), supporting our 
indication of an enhancing region within the +3299/+3447 fragment.  
III. 2. 2 Functional dissection of the second conserved region 
In order to narrow down the active sequence(s) within the intronic fragment +3299/+3447 of the 













Figure III. 2: SEAP activity of different TNW truncated intronic constructs of the region (+3299/+3447) in HT1080 
cells compared to the entire fragment (+3299/+3447). The experiment was performed in triplicates and repeated three 
times (error bars = SEM). 
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The fragment of 148bp was subdivided into three shorter fragments of roughly 50bp each 
(+3299/+3349; +3344/+3394; +3394/+3447) as well as combinations of them as indicated in 
Fig.III.2.                  3’-end region (+3394/+3447) was responsible for the induction of the 
reporter gene expression. In order to identify the shortest nucleotide sequences with activity 
within this sequence, we performed site-directed mutagenesis (Fig.III.3). A scrambled sequence 
(AGAGTGATCA) that does not display any transcription factor binding sites was substituted for 
successive 10nt contained in the fragment of 53bp (+3394/+3447) as indicated in Fig. III.3. 
Constructs were transiently transfected in HT1080 cells for 24h. As shown in Fig. III.3, alteration 
of the central 20 bp in this sequence (segments III and IV) led to complete loss of SEAP 
expression, indicating that this region is essential for transcriptional activation.  
All primers used for all promoter reporter constructions and their intronic locations are listed in 
table III.1. The sequences were cloned into the HindIII and NheI sites of the pSEAP vector. For 
the procedures for cell transfection and reporter gene assays, see Chiovaro et al., 2014. 
 
Figure III. 3: SEAP activity of different scramble-mutant +3394/+3447 constructs, containing the mutation at different 
position. Basic vector and the unchanged +3394/+3447 region used as controls. The experiment was performed in 
triplicates and repeated three times (error bars = SEM). 
III. 2. 3 Computational analysis of the second conserved region 
After the experimental determination of the active nucleotide sequences within the 53bp 
construct, Matlnspector analysis revealed the presence of important transcription factor 
elements at this location (Table III.3). Binding sites for the transcription factors AP1, SP1 and a 
cAMP response element (CRE) well known to enhance gene expression, were found in region 
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IV (116, 117). Their replacement with the scrambled sequence showed a decreased SEAP 
reporter activity, proving their role as enhancer elements. In contrast to these positive 
regulators, in regions I and VI elements with potential transcriptional repression activity were 
identified. The proximal sequence element (PSE) of RNA polymerase III-transcribed genes is 
located in fragment I presenting a binding site for PSE-binding transcription factors (PTF), 
including co-activators as well as co-repressors (118). Moreover, a binding site for ETS1 is 
located in the last 10nt of the sequence. ETS1 belongs to the ETS-domain family of transcription 
factors and many co-regulatory partners, whether co-repressor or co-activator, can be recruited 
to ETS domain proteins (119).     
                                   Table III. 3: Matlnspector analysis of TFs 
Matrix Family Matrix Strand Sequence   
V$SNAP V$PSE.02 + cttggCGTAagtagtattt 
V$AP1R V$BACH2.01 - acacccTGGGtcaggaaaaaa 
V$SP1F V$TIEG.01 + acccAGGGtgtgtgtcc 
V$CREB V$TAXCREB.02 - aaagaaGGACacacaccctgg 
V$ETSF V$SPI1.03 + ttctttggGGAAtttaagctt 
 
III. 2. 4 Influence of the first intron on human tenascin-W promoter activity 
The region located 512bp upstream of exon 1 has been shown to be important for the regulation 
of transcription of the tenascin-W gene (Chiovaro et al., 2014). In the next set of experiments we 
aimed to investigate the influence of the three intronic conserved sequences on tenascin-W 
promoter activity. Therefore, intronic fragments were cloned upstream of the 512bp tenascin-W 
promoter preceding the TSS as well as upstream of the shorter  252bp and 79bp-long tenascin-
W promoter construct (Fig.III.4), as diagrammed in Fig. III.5.  
Figure III. 4: Schematic model of the three conserved regions within the first intron (oval shape; I.blue, II.red, 
III.green). TATA box sequence is located in the minimal promoter (-79), upstream the TSS of tenascin-W gene. 
Intronic fragments were cloned upstream different truncated forms of the promoter (-512, -252, -79). 
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We termed the three conserved intronic modules as I. (+1178/+1909), II. (+2920/+3447) and III. 
(+4561/+5539) (Chiovaro et al., 2014). Plasmid constructs were transiently transfected in 
HT1080 cells in media containing serum for 24h before SEAP activity was measured (Fig.III.5). 
 
 
Figure III. 5: SEAP activity of intronic constructs (I., II., III.) located upstream of the regions with promoter activity 
(512bp and the shorter 252bp fragment). Intronic activity is compared with expression from single promoter regions, 
512bp and 252bp (violet-control). The experiment was performed in triplicates and repeated three times (error bars = 
SEM). 
 
The result was different depending on the length of the tenascin-W promoter used. For the long 
tenascin-W promoter, all intronic regions appeared to inhibit its activity, while region II had no 
effect on the shorter tenascin-W promoter. After exclusion of some transcription regulator 
binding sites from the 512bp fragment by truncation to 252bp, the promoter activity arising from 
the truncated region is no longer inhibited and even slightly enhanced by the presence of the 
second intronic module. In contrast, the first and third intronic modules negatively regulated the 
promoter activity regardless of the length of the promoter used.  
 
Since we identified the minimal basal promoter of tenascin-W within 79bp upstream of the 
transcription start site (TSS) of the tenascin-W gene (Chiovaro et al., 2014) we also cloned the 
three conserved intronic regions upstream of this minimal promoter. To elaborate on possible 
differences between cell types and hence to assess how the cellular identity may influence the 
specificity of intronic activity on the promoter, we used human osteosarcoma cells (Krib), human 
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colon carcinoma cells (HCT116), human lung carcinoma cells (H1838) and HT1080 cells as 
model systems.  
 
Figure III. 6: SEAP activity of intronic constructs (I.blue, +1178/+1909; II.red, +2920/+3447; III.green, +4561/+5539) 
located upstream the minimal promoter 79bp (violet). Intronic activity is compared with expression from single 
promoter region in the 79bp (hTNW-79bp). Experiments were performed in triplicates (error bars = SEM). 
  
Tenascin-W mRNA expression was observed in HCT116 and H1838 cells (Hendaoui I., data 
unpublished), and given the association of tenascin-W with the osteogenesis process (120), 
Krib osteosarcoma cells were used. Results presented in Fig.III.6 show how the first conserved 
(blue) region exhibits a transcriptional repression of the minimal basal promoter (79bp) in all cell 
lines. The minimal promoter (79bp) by itself results in high levels of reporter expression in 
HT1080 and HCT116 cells and the presence of any of the three intronic regions upstream of the 
(79bp) minimal promoter leads to impaired induction of gene transcription. High induction of 
reporter activity by the third conserved region (green) is found in H1838 cells, whereas in Krib 
cells highest promoter activity is detected in presence of the second conserved region (red). 
Thus, the intronic regions seem to affect tenascin-W transcription in a cell type-specific manner 
and may thus contribute to the regulation of tissue-specific gene expression in vivo. 
III. 2. 5 Intronic regions evolutionary conserved between human and mouse 
tenascin-W gene 
Genomic sequences of tenascin-W orthologs share a common intron/exon organization with the 
same junction sites between different species (101).  
To find possible local alignments of mouse and human intronic regions sequences were 
  m                      m        ’  LALIG        m    m      ASTA         (121). 
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Furthermore, the GC content was measured at the website http://tubic.tju.edu.cn/GC-Profile/ 
(Table III.3). The observed average identity of conserved sequences was 61.5 % (Table III.3). 
Changes in GC content reflect molecular evolution, giving suitable estimates of the sequence 
divergence among species (122). In addition, the content of CpG-islands positively correlates 
with gene expression levels (123). Evolutionary conservation of noncoding sequences can be 
indicative of transcriptional regulatory elements (124).  
 
Table III.3. Features of human and mouse intron 
      Locus   Total Intron length     % GC content  
% 
Identity   
mTNW 5593 bp   45.38%   Sequence 
hTNW 9448 bp   46%   61.5% 
 
 
Interestingly, the sequence alignments produced by LALIGN program show a particularly high 
similarity (69.4%) between human and mouse loci in the intronic region +3290/+3450 (gray 
boxes) (Fig.III.7). This corresponds exactly to the second conserved region analyzed before and 
indicates a common regulatory function in mouse and man. 
 
             3290      3300      3310      3320      3330      3340 
Human  CAGTGGCTAGAAATTGGCTACCTCTCTTCTTTGGCGTAAGTAGTATTTTTTTTTTCCTGA 
       ::::::::::::  :::: ::  ::::  ::::  :::::::: :::::::    :::::  
Mouse  CAGTGGCTAGAAGCTGGCAACTGCTCTA-TTTGAAGTAAGTAGCATTTTTT----CCTGA 
           2600      2610      2620       2630      2640            
 
             3350      3360      3370      3380      3390      3400 
Human  CCCAGGGTGTGTGTCCTTCTTTGGGGAAAATGAGGTGACACAGAAACCATCCACCCCTGG 
       : :::  :::::::: :::::: : ::::::::::::::::: :  :::: :: : ::   
Mouse  CTCAG--TGTGTGTCTTTCTTTAGAGAAAATGAGGTGACACAAAGGCCATACAGCTCTAA 
      2650        2660      2670      2680      2690      2700      
 
             3410      3420      3430       3440      3450          
Human  GGTCCAAGAGGACCATCAGGATTCAGGGGCCATC-CTCCTCCCTTGGCCAAGGCTTGGAT 
        :    ::: : :: :  : : : ::   :  :: :::::::       ::::::::: : 
Mouse  TG----AGAAGTCCTTGTGAACTGAGAAACATTCTCTCCTCCT------AAGGCTTGGTT 




Figure III. 7: Sequence alignment of the +3290/+3450 region 
Sequence alignment of the sequence (+3290/+3450) within the second intronic conserved region between human 
and mouse tenascin-W.  
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Due to the similarities between the human and mouse intronic sequences, we investigated the 
activity of the human intronic regions in mouse HC11 cells. Single intronic sequences or 
combinations thereof were cloned upstream of the SEAP reporter gene and these constructs 
were transiently cotransfected with a luciferase expression vector as internal standard for 
transfection efficiency. All values were compared to the negative control (pSEAP Basic, empty 
vector) and similarly to the results obtained in HT1080 (Chiovaro et al., 2014), the highest SEAP 
expression was observed with the shortest fragment within the second intronic conserved region 
(+3299/+3447). Thus, we conclude that the human intronic fragments show equal functional 
activity in a mouse in vitro-environment (Fig.III.8).  
Figure III. 8: SEAP activity of different combination of human intronic regions transfected in HC11 cells. The second 
green line in the UCSC Genome Browser representation (indicated with a red cross, on the left) displays the 
evolutionary conservation track on the mouse. Basic vector is used as negative control. Experiment was performed in 
triplicates and repeated three times (error bars = SEM). 
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The in silico (Fig.III.7) and experimental (Fig.III.8) analysis of intronic regions show a very high 
functional similarity of the fragment +3299/+3447 in both mouse and human. Therefore, we 
performed transcriptional regulator binding site predictions using ConSite. Potential transcription 
factor binding sites, which are conserved between human and mouse tenascin-W gene, are 
shown in figure III.9. 
 
 
Figure III. 9: Potential transcription factor binding sites in the second intronic conserved region   
The potential transcription factor binding sites located in the region +3290/+3450, which are conserved between 
mouse tenascin-W (blue) and human tenascin-W (green) are shown. Their specific binding motif as well as their exact 
positions is indicated in the table (bottom). 
  
III. 2. 5. 1 Conserved transcription factor binding sites in human and mouse tenascin-W 
gene orthologs 
An overall profile of transcription factor binding sites displayed several elements associated with 
an enhancer-like activity. SOX binding sites are for instance found in the Nestin neural enhancer 
(125), and the            5’-flanking region of the PDGF promoter contains an enhancer 
harboring an ELK/E74A motif (126), while AGL-3 factor drives BMP7 gene expression in kidney, 
eye, and limb by binding an enhancer region within its first intron (127), and finally Snail 
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negatively modulates the expression of E-cadherin, Claudins, Occludin and Mucin-1 genes by 
binding to the E-box enhancer sequence (128-130).  
III. 2. 6 Transcription Start Site of the mouse tenascin-W gene  
Expression of mouse tenascin-W following BMP2 treatment in HC11 cells (131), prompted us to 
use these cells to detect the TSS of the mouse tenascin-W gene. Rapid amplification of cDNA 
     (RAC )           m             y     5’     of the mouse tenascin-W transcript. Bands of 
400bp were detected on the agarose gel after two rounds of PCR with the adapter specific inner 
primer (PCR anchor primer) and the nested gene specific reverse primers (Fig.III.10). 
Sequencing revealed that these fragments corresponded to the ATG-containing exon and a 
non-translated exon 1 consisting of 99bp. In the genomic DNA exon 1 is located 5593 bp 




Figure III.10:  5’RACE PCR 
(A) One microliter aliquot of a 1/20 dilution of the amplification product of dA-tailed cDNA was used as template for 
the second PCR. Second PCR was performed using a combination of two gene specific reverse primers mSP3 and 
mSP4. (B) Sequence of the first non-        x               5’RAC          . I           99b . G  y b x           
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III. 2. 6. 1 Characterization of the mouse tenascin-W promoter  
Our results allowed us to map the transcription start site upstream of the first non-coding exon of 
the tenascin-W gene in both human (Chiovaro et al., 2014) and mouse species. Prompted by 
the similarity between these two orthologous genes we decided to functionally characterize the 
mouse tenascin-W promoter region within 2kb upstream of the first exon as we already did for 
the human tenascin-W promoter (Fig.III.11). Various constructs containing this 2kb region and 
several truncated forms were transiently transfected in HC11 cells for 24h. The high SEAP 
reporter activity obtained from the construct including the 200bp upstream of the TSS implies 
that this fragment still contains the main sequence with promoter activity.  
 
Figure III.11: SEAP activity of mouse tenascin-W promoter constructs. Gene expression is compared with the 
negative control (SEAP-basic). Experiment was performed in triplicates (error bars = SEM). 
 
As expected, the sequence alignments generated by the LALIGN program between human and 
mouse promoter regions showed a high degree of conservation (76.7%) (Fig.III.12).In this 
figure, the sequences highlighted in gray show exon1. Comparison between human and mouse 
reveals the presence of a TATA box sequence in both species (dark blue). A conserved Smad 
binding site was observed 335bp (light green) upstream of the TSS in mouse, whereas, the 
human Smad motif (dark green) present in the minimal promoter (-79) (Chiovaro et al., 2014) 
did not show any alignment with the mouse sequence.  
 




              10        20        30        40        50        60 
Human  ATTTTAAAAGCAGTAGGCAGGAAGTCCCAGAATGCCTGAAACAGGAAAAAGAGAAAGAAA 
       ::::::  :: :::: :::: :::: :::::::: ::: :::: ::::::::::       
Mouse  ATTTTAGGAGGAGTAAGCAGCAAGTTCCAGAATGTCTGGAACATGAAAAAGAGA------ 
               10        20        30        40        50           
 
               70        80        90       100       110       120 
Human  CTTTATAAATGCACTTTTGAACCCCGAGACCCAGCTCCTGGCCAGGAGACAGGCAAACTC 
       ::: :::::: ::::::  ::::: ::::: :::::::::::::::::::: ::::::   
Mouse  CTTAATAAATACACTTTCAAACCC-GAGACTCAGCTCCTGGCCAGGAGACATGCAAACG- 
           60        70         80        90       100       110    
 
              130       140       150       160       170       180 
Human  TTTTAATATCCTTATTCTGGATTCACTTAAATGGAAACAGCCTCCAGTATTTTTAGCTGC 
       ::::::::::::: ::::: ::: ::::::::::::::::::    :::::::::::::: 
Mouse  TTTTAATATCCTTGTTCTGCATTTACTTAAATGGAAACAGCCCGTGGTATTTTTAGCTGC 
            120       130       140       150       160       170   
 
              190       200       210        220         230        
Human  TGTGTAATCAAAGTGAAAAAGAAGAAGGAAATGTATA-TATTTTTCTTTC--CTAGTTAG 
       ::::::::::: :: :: ::: : : :: :::::::: : :::::: :::  :::::::: 
Mouse  TGTGTAATCAACGT-AAGAAGGAAAGGGGAATGTATACTTTTTTTCCTTCTCCTAGTTAG 
            180        190       200       210       220       230  
 
       240       250       260       270       280       290        
Human  AATAAGAGAAGGAATTGCTCATTATCTTTTAGCAGAGTCCCTGCTAGGAAGGGAGGAAAA 
       : :::::::: :::::::::: :   : : : ::::::::     ::::::::::::::: 
Mouse  AGTAAGAGAATGAATTGCTCAAT---TCTCAACAGAGTCC-----AGGAAGGGAGGAAAA 
             240       250          260            270       280    
 
       300       310          320       330       340       350     
Human  CACCAGGAGTCTCC---ATTTGCTCCTCCTCTGGCCTAGACAGGATTTAAACCCAGGAAG 
         :: :::::: :    ::: :::::::::::: : ::: :  :::::::::::::: :: 
Mouse  T-CCCGGAGTCCCATTGATTGGCTCCTCCTCTGTCATAGCCTTGATTTAAACCCAGGGAG 
            290       300       310       320       330       340   
 
          360       370       380        390       400       410    
Human  GGAAGCCAAGGAGAGACGAGAACCAGGGACG-ACCAGCAAGTACCAAGGTCTGCGGCAGG 
       ::::::  ::: :::: :: :   ::::::: : : ::::    : : :::: : : :   
Mouse  GGAAGCAGAGG-GAGAAGATATTGAGGGACGGATCGGCAA----CGAAGTCTCCAGTACC 
            350        360       370       380           390        
 
           420       430        440       450       460       470   
Human  AGGAGACCGGCTCACAGGAG-CAGCAGCATTGGAAGAGGCACCCAGCAGCCTCCCAGGTA 
       ::::  :: ::::::::::: :::  : :::::::: ::  ::::::::::::::::::: 
Mouse  AGGA--CCAGCTCACAGGAGGCAGGGGGATTGGAAGTGGTGCCCAGCAGCCTCCCAGGTA 
       400         410       420       430       440       450      
 
            480       490        500       510       520     
Human  AGAGTGCCAGTTGCCCAAG-CTTTACTTACTGGAGGGAGGGAGGTGGCCAATG 
       :::::::::: : :   :: :::::    :    ::::::: :   : :: :: 
Mouse  AGAGTGCCAGCTCCTTGAGGCTTTATCATCGATTGGGAGGGGGACAGTCAGTG 
                       460       470       480       490       500         
Figure III.12: Sequence alignment between human and mouse tenascin-W promoter regions (LALIGN program). 
Both human and mouse TNW gene are endowed by a TATA-box promoter (blue). In gray is underlined the exon 1. 
Conserved Smad motif (light green) in both species was detected 335bp from the mouse gene TSS (pink). The 
human Smad sequence for TGF signaling is indicated in dark green (Chiovaro et al., 2014). Bidirectional Hoxc-8 
gene was found 193bp upstream of TSS in mouse tenascin-W promoter (light blue).  
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Moreover, we were able to identify a binding site for the transcription factor Hoxc-8 (light blue), 
placed 193bp upstream of the TSS of the mouse tenascin-W promoter.  In this case the binding 
site is located on different DNA strands. In the mouse, the binding site for Hoxc-8 is located on 
the negative strand (TTGATTACAC), whereas, in human it is found on the positive strand 
(GTGTAATCAA). The different arrangement of binding sites could influence the binding 
preferences itself of transcription factor and in turn affect the gene regulation.  
III. 2. 7 Tenascin-W expression in cell cultures 
III. 2. 7. 1 Human osteosarcoma models 
Previous studies in our lab aimed to detect endogenous human tenascin-W expression in 
human cell lines. Previous reports published in 2004 and 2005, have shown the expression of 
tenascin-W in primary mouse embryonic fibroblasts (MEFs) upon treatment with the growth 
factor BMP2 and the cytokine TNF (104, 131). BMP2 also induced tenascin-W expression in 
mouse myoblast cells (C2C12), parallel to their differentiation into osteoblasts (104, 131). 
Although mouse embryo fibroblast cells were expressing tenascin-W, this was not the case for 
human fibroblast lines, such as Detroit (skin), MRC5 (lung) and IMR90 (lung), which did not 
show any detectable tenascin-W levels (Degen M., data unpublished). Given the well-known 
role of tenascin-W during embryonic bone development (120), we decided to investigate if 
human bone marrow stem cells (BMSCs) will express tenascin-W following their differentiation 
into osteoblasts. Indeed tenascin-W protein expression was detected in BMSCs treated with 
osteogenic medium (Martina E., data unpublished).  Prompted by these results, we investigated 
human osteoblast models for tenascin-W expression. We tested whether the same osteogenic 
medium (OM) previously used for BMSCs could also induce tenascin-W expression in human 
osteosarcoma cell lines Saos-2 and U2OS.  
 
 
Figure III. 13: Detection of human tenascin-W mRNA in human osteosarcoma cell lines U2OS 
The mRNA from untreated (first two columns) and OM-treated U2OS cells was isolated and tenascin-W expression 
was assessed by RT-PCR. TNW mRNA expression was shown by the bands at 149bp and 265bp.  
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The expression of tenascin-W in U2OS as well as in Saos-2 cell lines was assessed by RT-
PCR. We were able to observe tenascin-W mRNA expression exclusively in U2OS cells after 
treatment with osteogenic medium (Fig.III.13). For this assay, we used two distinct pairs of 
primers for tenascin-W mRNA listed in table III.2. Moreover, tenascin-W protein expression was 
revealed by immunofluorescence staining of U2OS and Saos-2 cells kept in osteogenic medium 
for one week. In the first panel, (Fig.III.14-A) strong tenascin-W staining is displayed on the cell 
surfaces and as reticular fibers assembled around U2OS cells, whereas in Saos-2 cells the 
tenascin-W staining is weak and given the fact that no mRNA could be detected may represent 















Figure III.14: Detection of human tenascin-W protein in human osteosarcoma cell lines    
U2OS (A) and Saos-2 (B) cells were cultured in osteogenic medium (first and third row) or growth medium (second 
and fourth row) for one week. Cells were immunostained with anti-tenascin W monoclonal antibody and Alexa-488 
secondary antibody for detection.  
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III. 2. 7. 2 Mouse and human mammary epithelial cells 
 
The investigation of the role of tenascin-W in migration and proliferation of metastatic (4T1) or 
normal (HC11) murine mammary cell lines showed a specific role of BMP2 in inducing tenascin-
W protein exclusively in HC11 cells (131). Therefore, we tested BMP2 as potential inducer of 
tenascin-W in mouse as well as human normal mammary epithelial cells.  
 
 
Figure III.15: Endogenous mouse tenascin-W protein expression in HC11 cells 
HC11 cells were treated (+) or not (-) with BMP2 (100ng/ml) for 48h. Supernatants (M) and cell lysate (Lys) were 
analyzed for mouse tenascin-W expression.   
  
 
We were able to detect tenascin-W protein both in cell extracts and conditioned medium of 
HC11 cells treated with BMP2 (Fig. II.15). In the case of the human mammary epithelial cells  
we analyzed the expression of tenascin-W in MCF10A cells treated or not with BMP2 by RT-
PCR using cDNA from BMSC-derived osteoblasts (Martina E., unpublished data) as positive 
control (Fig.III.16). Indeed, the specific 149bp band was detected in BMP treated MCF10A cells 
by using TNW primers listed in table III.2.  
 
 
Figure III.16: Endogenous human tenascin-W mRNA expression in MCF10A cells 
MCF10A cells were treated (+) or not (-) with BMP2 (100ng/ml) for 24h. cDNA from BMSCs differentiated in 
osteoblasts was used as positive control.    
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Although mRNA was detectable, we were not able to detect the endogenous protein in the 
corresponding cell line by immunoblotting. 
III. 2. 8 Immunohistochemistry of bone metastases of breast cancer 
Positive immunofluorescence stainings of mouse tenascin-W expression was performed on 
bone sections of mice harboring bone metastases of breast cancer (see Chiovaro et al., 2014). 
In addition, we investigated the distribution of tenascin-W protein in sections of metastatic bone 




Figure III.17: Immunohistochemistry of sections of bone metastases of breast cancer 
Immunohistochemical staining of mouse tenascin-W (brown). In the right panels a higher magnification (20X) of the 
section indicated by squares in the respective left panels is shown. Sections were counterstained with hematoxylin.  
 
The tumor cells of the metastatic foci appear as a dense mass of cells exhibiting blue oval and 
round shapes. Tenascin-W protein, stained brown, seems to wrap and infiltrate the tumor nests. 
Staining of tenascin-W surrounding circular structures embedded in the tumor could suggest a 
potential role of tenascin-W in promoting the generation new blood vessels.   




IV. 1 Tenascin-W as a component of adult stem cell niches in healthy and 
pathological conditions 
Tenascin-W is the fourth and last discovered member of the tenascin family. Several reports 
have attributed to tenascin-W an important role in osteogenesis (120) and in periodontal 
ligament differentiation (132). Tenascin-W was also found in the adult stem cell niche of the 
aortic valve and in the periosteum of ribs (104). These different sites of expression, besides 
indicating the physiological conditions in which tenascin-W plays an active role, also highlight 
tenascin-W as a stem cell niche component involved in mechanisms of cellular differentiation 
(133). Although so far we have mentioned the bright side of tenascin-W, it is mostly cited for 
being a cancer biomarker in human solid tumors (109). The persistent tenascin-W expression in 
the stroma of colon and breast tumors and in gliomas, as well as the expression in the proximity 
of blood vessels has prompted us to explore tenascin-W in breast cancer metastasis to bone.  
IV. 2 Tenascin-W expression in bone metastases of breast cancer: future 
directions of investigation    
In our studies, we were able to identify tenascin-W as a component of the stromal niche hosting 
bone metastases of breast cancer. Our in vitro model tried to mimic what may occur when 
cancer cells located at a primary site start to metastasize. More precisely, circulating cancer 
cells, or also cancer cells still residing within the primary tumor site, can induce the 
establishment of a special distant niche to favor their subsequent metastatic engraftment by 
releasing a wide range of cytokines and growth factors into the bloodstream (134). As a 
consequence, the stromal compartment adopts an engraftment-permissive state following the 
arrival of the tumor-secreted factors. In particular, we observed the expression of tenascin-W 
protein following TG β-induced myofibroblastic differentiation of bone marrow stem cells. 
Moreover, we showed increased proliferation and migration rates of MDA-MB231-1833 breast 
cancer cells in the presence of recombinant tenascin-W protein. In our experiments, the role of 
tenascin-W on cancer cells was assessed independently of the stage of metastatic 
development.  It would be interesting to investigate tenascin-W activity during each stage of 
breast cancer cell spreading in order to achieve a more refined framework of all different 
tenascin-W contributions in tumor and metastatic progression. Our experimental data may be 
oversimplified and in reality everything will be much more complicated, and a more holistic 
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observation would be needed to uncover specific cross-talks among several factors which are 
omitted in restricted in vitro systems.  
IV. 3 How could tenascin-W influence the different developmental stages of 
cancer? 
In our analysis of the transcriptional tenascin-W regulation, we have detected a promoter 
binding site for Smad4, which is a mediator of TGF signaling, as well as an intronic nGRE 
element. The roles of both of these regulatory sequences were experimentally investigated. 
Further analysis of the second intronic region (+3290/+3450) showed a binding site (E-box, 
GAGGTG) for the transcription factor Snail, which is conserved between human and mouse 
(Fig.III.9). Snail is transcriptionally controlled by signals including TGF, EGF, FGF, Wnt, TNF- 
and other factors such as hypoxia or estrogen (135). It has been shown that Snail itself can form 
a complex with Smad2/3, acting as a repressor of the expression of cell-adhesion molecules, 
such as E-cadherin, occludin and claudin-3 (136). Moreover, Snail promotes the sprouting of 
endothelial cells in vitro (137) and the proliferation of tumor cells, for instance of melanoma 
cells, by inhibiting tumor suppressor CYLD (138).  
In light of these data, it would be reasonable to speculate on one hand about an involvement of 
TGF in regulating the expression of both Snail and tenascin-W, and on the other hand about a 
potential enhancing/supportive role of Snail in the migration/proliferation-promoting activity of 
tenascin-W on breast cancer cells.  
Interestingly, further immunohistochemistry of bone metastases of breast cancer sections 
revealed a remarkable tenascin-W protein expression surrounding the tumor mass, suggesting 
a possible involvement in blood vessel formation for the infiltration of tumor cells. This 
hypothesis is supported by many other previous studies which have detected a correlation 
between immunofluorescence staining of tenascin-W with von Willebrand factor in glioblastoma 
(108) and also a co-staining with CD31 in proximity to blood vessels in lung and kidney tumors 
(109).  
Therefore, tenascin-W might sustain the dissemination and the subsequent engraftment of 
breast cancer cells to the bone by inducing angiogenesis. Following the initial promoting phase, 
TNW may regulate the proliferation of tumor cells during the metastatic process. This working 
model of tenascin-W activity, which follows a time-course of events in tumor development would 
need further investigation. It would be interesting to analyze whether the transcription factor 
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Snail acts synergistically with tenascin-W in the bone metastatic context by inducing tenascin-W 
transcription.  
Thorough analysis of a role of tenascin-W in bone metastases of breast cancer could be 
performed by omitting or increasing its expression in vivo. However, it is well known that one 
issue regarding the knockout of ECM proteins is the compensation through other well-
characterized matrix proteins. For instance, mice deficient for tenascin-C still present a normal 
skin wound healing and possibly tenascin-W has a compensatory role in inhibiting cell-
adhesion, which is essential for tissue repairing (139). Also, within the matrilin protein family, a 
temporary regulation of matrilin-4 to compensate for the lack of collagen fibrillogenesis activity 
caused by the double knockout of the genes matrilin-1/3 was observed (140). Therefore, in both 
cases, no striking phenotype was detected. The ectopic expression of tenascin-W in normal 
tissue of transgenic mice could give some hints on its contributions during the appearance of a 
tumor and its metastatic progression. Alternatively, conditional mutants lacking the tenascin-W 
gene in the bone only, through Cre recombinase-mediated ablation, or the use of inducible 
siRNA/shRNA in mice harboring tumors could allow us to better monitor significant changes in 
tumor regression depending on the presence or absence of tenascin-W.   
IV. 4 Targeting of TGF signaling pathway in bone metastases of breast 
cancer 
Statistically, 70% of patients with advanced breast cancer display metastases preferentially in 
bones, which leads to clinical complications collectively referred to skeletal-related events, 
including significant tissue morbidity associated to osteolytic lesions, bone infiltration and 
pathological fractures (141). Bone tropism is also shown for prostate cancer; in this case 
however, unlike breast cancer, the tumor is responsible for an excessive osteoblast activity, 
which leads to atypical new bone formation (142, 143). The local breast tumor 
microenvironment contains the support for the metastatic spreading and it was shown to be 
enriched in TGF together with other factors (144-146). In our experiments we have shown a 
regulation of tenascin-W expression in the bone marrow metastatic niche by MDA-MB231-1833 
cells through Smad4-mediated TGF signaling. Nevertheless, additional TGF can derive from 
osteoclastic bone resorption following the secretion of osteolytic factors from breast cancer cells 
(147). In turn, the release of TGF within the bone metastatic niche might indirectly support 
tumor cell proliferation through further induction of tenascin-W expression. Now the question to 
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address is how to keep this vicious cycle between breast cancer cells and osteoclasts under 
control.  
Currently, the use of bisphosphonates has aimed to achieve a reduction in bone turnover and 
consequently to control bone resorption (148). Further potential interventions with the metastatic 
development have aimed at the possibility of interfering with the early stages of tumor 
progression. BMP7, unlike TGF, is an inducer of MET during for instance embryonic 
development (149) and it has been shown to counteract the ability of TGFto induce EMT in 
MDA-231 cancer cells (150). Moreover, BMP7 inhibits the invasive phenotype of MDA-231 
cancer cells by interfering with TGF-induced integrin 53 expression (151). The direct 
targeting of TGF includes the use of the panTGF-neutralizing mouse monoclonal antibodies 
1D11 and 2G7, or TGF receptor inhibitors impairing the kinase catalytic activity of TRI/ALK5 
including SB-431542, Ki26894 or LY364947 (147). In order to increase the efficiency of these 
molecules, it is possible to apply a combination therapy approach by using in addition various 
cytotoxic agents.  
IV. 5 Counteracting the establishment of a stromal metastatic niche  
One of the major problems associated with metastatic development is the inability to monitor it 
during its early stages of growth. This leads to the inefficacy of many drugs, which at advanced 
stages can no longer counteract the spread of cancer. The survival of tumor cells in the 
circulatory system is low and only a tiny fraction of cancer cell clones within the primary tumor is 
capable of colonizing a secondary organ (152). In addition, the migration out of the primary 
tumor site in order to find a permissive distant environment is the most delicate stage wherein 
cancer cells show their weakness and can be more sensitive to certain drugs conjugated with 
specific nanoparticles (153, 154). However, once arrived at the distant destination, what is really 
essential for the tumor cells is the interaction with the surrounding local stromal 
microenvironment, through which they can manifest their malignant features. Therefore, it is 
extremely valuable to take into account all possible strategies to handle the metastasis-
promoting contributions arising from the metastatic niche. 
 
Infiltrating tumor cells require oxygen and nutrients, which are supplied from newly formed blood 
vessels. Neovascularization in secondary sites is independent of tumor size and it can be 
modulated by tumor-secreted factors (155). In our experiments, immunohistochemical analysis 
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of bone metastases of breast cancer indicated a perivascular tenascin-W deposition pattern. 
This could suggest a role of tenascin-W in promoting tumor vascularization, which in turn would 
make tenascin-W a potential candidate for anti-angiogenic therapy. Moreover, as already 
mentioned, the increased ECM deposition in an altered stroma is caused by activated 
fibroblasts (CAFs). All the external signals are then transduced to the nuclear level by the ECM-
integrin-cytoskeleton axis. In this regard, we have discussed the role of BMP7 in inhibiting 
TGF-induced integrin 53 expression (151) and, in addition, it has been shown that the 
blockade of 53 integrin receptors had a beneficial effect on breast cancer bone metastases 
by reducing the bone resorption (156). Treatment with the 53 integrin receptor inhibitor 
cilengitide showed a reduction in angiogenesis and in the localization of ECM proteins to blood 
vessels as well as an increased intratumoural vascular permeability, which collectively impaired 
osteoclast activity (156).  
Vascular permeability highly influences the clinical outcome of drug delivery. For instance, the 
increased ECM deposition along the vessel walls with the consequent increased stiffness 
causes a high fluid pressure, which can impair drug penetration through tumor vessels. All 
current strategies based on the combination of anti-angiogenic and vascular normalization 
agents with traditional therapies aim to overcome and improve all those limits associated to the 
failure of chemo-radiotherapy.  
IV. 6 Definition of human and mouse tenascin-W cellular sources 
In summary our studies identified the tenascin-W protein as a component of the activated stem 
cell niche in the bone (working model, Chiovaro et al., 2014). Moreover, we sought for tenascin-
W protein expression in human osteosarcoma cell lines Saos-2 and U2OS as well as in human 
mammary epithelial cells MCF10A. We were able to observe tenascin-W mRNA expression in 
U2OS and MCF10A cells (Fig. III, 13-16) and by immunofluorescence analysis tenascin-W was 
investigated in Saos-2 and U2OS cells (Fig. III.14). However, we did not take these cell lines 
into account as systems to explore tenascin-W regulation because of their low tenascin-W 
protein expression levels.  
 
Previous studies have detected mouse tenascin-W protein expression in 4T1 epithelial breast 
cancer cells by TNF, in MEFs and in HC11 mouse mammary epithelial cells by BMP2 (131). 
Therefore we used the HC11-expression system for the induction of tenascin-W by BMP2 for 
the isolation of mRNA to identify the transcription start site. This led to the identification of a TSS 
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at a first non-coding exon 147bp upstream from the ATG start codon present in exon2 (Fig. 
III.10). Promoter activity was located within 200bp upstream of the TSS (Fig. III.11), wherein, 
alignments produced by LALIGN program also showed a TATA box sequence (Fig. III.12). 
Further comparison analysis of mouse and human tenascin-W gene loci showed specific 
binding sites not only in the promoter but also in the first intron. Conserved repressive domains 
for glucocorticoid receptor (nGRE) located in the mouse intronic sequence could explain the 
similar negative modulation of gene expression driven by the first human conserved region 
transfected in HC11 cells (Fig.III.8). Many other transcription factor binding sites located in the 
region +3290/+3450 were conserved between mouse and human tenascin-W gene (Fig.III.9). 
Interestingly, the mouse promoter region was characterized by a unique exposure and 
rearrangements of binding sites for transcription factors. We observed a different placement 
(335bp upstream the TSS) for the mouse Smad motif (aatGTCTggaa) compared to the human 
one, which was located within the 79bp upstream the TSS. Moreover, in proximity of the mouse 
Smad motif we also observed a binding site for the homeobox gene Hoxc-8 
(tacgttgATTAcacagcag). The Hoxc-8 transcription factor plays an important role in the mouse 
embryonic development wherein it is highly expressed in the limbs, backbone and spinal cord 
(157). Xingming Shi et al., have shown the direct interaction between Smad1 and Hoxc-8 
detected by a yeast two-hybrid system and the direct control of the osteopontin gene 
transcription by BMP2 is mediated by a Hoxc-8 binding site (158). This could suggest a 
differential control of mouse tenascin-W by BMP2 signaling through Hoxc-8 and Smad1 
depending on the context. Moreover, Hoxc-8 gene has been shown to play important roles in 
tumorigenesis and precisely, its depletion was associated with the inhibition of cell migration, 
invasion and metastasis of breast cancer cells (159). Given the tenascin-W expression in tumor 
stroma of breast cancer (105), we may speculate that Hoxc-8 could act as transcription 
regulator for mouse tenascin-W also in pathological conditions. The differential tissue-specific 
regulation of mouse as well as human tenascin-W may lead to a divergence of binding sites 
between human and mouse. 
The differential tenascin-W gene transcription control can be dictated by species-specific 
physiology and behavior of human and mouse. It could be affected by the distribution and the 
different organization of transcription factor binding sites among orthologous promoters which in 
turn would imply the acquisition or loss of functional regulatory elements. Thereby, a thorough 
analysis of the evolutionary sequence conservation between species could have a significant 
impact for medical research.  




V.1  Experimental procedures (unpublished data) 
Cell culture   
 
Mouse mammary epithelial cells (HC11) were grown in RPM1640 medium supplemented with 
10% FBS, 5ug/ml insulin and 10ng/ml EGF. Human mammary epithelial cells (MCF10A), kindly 
provided by Dr Mohamed Bentires-Alj (Basel, Switzerland) were cultured in DMEM/F12, 5% 
horse serum, 10ng/ml EGF, 0.5mg/ml Hydrocortisone, 100ng/ml cholera toxin and 10mg/ml 
insulin. Human osteosarcoma Saos-2, Krib and U2OS                        α-MEM containing 
10% FCS, 1% HEPES, 1% sodium pyruvate, 10 mM glutamine (control medium), supplemented 
with 5 ng/mL FGF2. Osteogenic differentiation medium consisted of control medium 
supplemented with 100 nM dexamethasone (cat #D-2915, S  m ), 10 mM β-glycerophosphate 
(cat #G-9891, S  m ),     100 μM      b        2-phosphate (cat #A-8960, Sigma). Colorectal 
       m        (HCT116)               M  C y’  5A m    m       m           10%   S. 
Human lung carcinoma cells (H1838) were cultured in RPMIB medium which was including 
RPMI 1640 with 1.5g/L sodium bicarbonate, 2mM glutamine, 1mM sodium pyruvate and 10mM 
HEPES.  
Cloning of intronic reporter constructs upstream the human tenascin-W promoter 
Intronic conserved regions were inserted into NheI/HindIII sites of the pSEAP-basic vector, 
whereas human tenascin-W promoter sequences had NheI/XhoI sites for directional cloning 
(Chiovaro et al., 2014). Promoter constructs pSEAP-TNW (-512bp), pSEAP-TNW (-252bp), and 
pSEAP-TNW (-79bp), were digested first with NheI enzyme and after 1h at 37oC to inactivate 
the enzyme function the product was incubated at 72oC for 15min. In order to convert the 
fragmented DNA into blunt-end, it was treated with DNA polymerase I, Klenow enzyme in the 
presence of dNTPs for 1h. Second digestion was performed with MluI restriction enzyme for 1h 
at 37oC. To obtain intronic inserts, digestion with MluI and NruI enzymes was carried out. The 
restriction fragments were gel purified.  
Immunofluorescence staining of human osteosarcoma cell lines 
Saos-2 and U2OS cells were cultured on 8-chambers slide (BD Falcon) either in control or in 
osteogenic medium for one week. Cells were then fixed for 15 min in 4% formaldehyde at RT, 
rinsed with PBS and additionally fixed for 10 min in methanol at -20°C. After 30 min blocking at 
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RT in blocking buffer (PBS/0.01%Tween, 1% BSA), cells were incubated over night at 4°C in 
blocking buffer containing the primary antibody. After three washes in PBS, cells were incubated 
for one hour at RT in PBS/0.01%Tween containing the Alexa-488-conjugated secondary 
antibody (1:200) and Hoechst (1:2000). Cells were then washed three times with PBS and 
mounted in ProLong Gold Antifade reagent (Invitrogen). Pictures were acquired using an Axio 
Imager Z2 LSM700 confocal microscope (Zeiss) and processed with ImageJ. 
Mouse tenascin-W protein detection  
HC11 cells were seeded at a density of 7x104 into 6 well with RPM1040 10% HS and incubated 
overnight. Subsequently, the medium was replaced with RPM1040 serum free, cointaing or not 
BMP2 (100ng/ml) for induction of mTNW. Following 48h from the treatment, supernatants and 
cell lysates were solubilized for 5min at 95°C in SDS-PAGE sample buffer, followed by 
electrophoresis on 6% gel polyacrilamide gels. Proteins were electro-transferred onto PVDF 
membranes (Millipore). After blocking for 1h at room temperature in TBS with 0.05% Tween and 
5% skim milk powder, membranes were incubated overnight with the polyclonal rabbit anti-
mouse TNW primary antibody, washed and then incubated for 1h with the appropriate 
secondary antibody coupled with HRP (1/10 000). Specific staining was revealed using ECL kits 
(Amersham). HC11 cells treated with BMP2 express mTNW.  
5’RACE for transcription start site determination of mouse tenascin-W gene 
 
T            z      5’        m   e tenascin-W mR A   q     ,     5’/3’ RAC     , 2nd 
G          (R    )                           m           ’              . mR A              
from HC11 cells previously treated with BMP2 (100ng/ml) for 48h by using Dynabeads mRNA 
Direct Kit (Invitrogen). cDNA was synthesized from 1g of mRNA using the mouse tenascin-W 
            m   mS 1. T         y     5’        T   mR A                  m             . 
The resulting PCR fragments were ligated into pBluescript KS vector (Stratagene) and 
sequenced.   
Table V. 1: Sequences of the primers used for the 5’ RACE 
 









Immunohistochemistry experiments were performed on Ventana DiscoveryXT instrument 
(Roche Diagnostics, Manheim) with the procedure Research IHC DAB Map XT. Frozen slides 
were thaw for 20 min on air and placed in the machine where they were covered with Reaction 
buffer (Roche Diagnostics) before starting the run. In the instrument, slides were fixed with 
Formal-Fixx 1:2 (Thermo scientific) for 12 minutes. Rabbit anti-mouseTNW was applied 
manually at a dilution of 1:100 and incubated for 1 hour at 37°C. For the detection we used 
ImmPRESS anti-rabbit Ig (peroxidase) polymer reagent (Vector laboratories MP-7401) which 
was manually applied and incubated for 32 minutes at 37°C. Sections were finally 
counterstained with Hematoxylin II and bluing reagent (Roche Diagnostics) for 4 min, 
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Primer for +3299/+3447 deletion                       Position 
        
  
  
FW:             5’-CAGGATGAGATAATAAGGGA-3’                  (+3299/+3447) 








FW:             5’-CAGGATGAGATAATAAGGGA-3’                  (+3299/+3349) 








FW:             5’-ATAAAGGTCTGTAACAGTGGCT-3’                                   (+3344/+3394) 








FW:             5’-TTGGCGTAAGTAGTATTTTT-3’                                                    (+3394/+3447) 
RV:              5’-TTCCCCAAAGAAGGACACAC-3’ 
  
  
        
  
  
Site-Directed Mutagenesis for  +3394/+3447     
I. FW:5’-GCGTGctagAGAGTGATCAGTAGTATTTTTTTTTTCCTG-3’   
  RV:5’-AAAATACTACTGATCACTCTctagCACGCGTAAGAGCTC-3’ 
  
     
  
II. FW:5’-gCTTGGCGTAAAGAGTGATCATTTTTTTCCTGACCCAGGG-3’ 
  RV:5’-CAGGAAAAAATGATCACTCTTTACGCCAAGctagCACGC-3’ 
  
     
  
III. FW:5’-GTAGTATTTTAGAGTGATCAACCCAGGGTGTGTGTCCTTC-3’ 
  RV:5’-CACCCTGGGTTGATCACTCTAAAATACTACTTACGCCAAGc-3’ 
  
     
  
IV. FW:5’-TTTTTTCCTGAGAGTGATCATGTGTCCTTCTTTGGGG-3’   
  RV:5’-GAAGGACACATGATCACTCTCAGGAAAAAAAAAATACTAC-3’ 
  
     
  
V. FW:5’-GACCCAGGGTGAGAGTGATCATTTGGGGAAAAGC-3’   
  RV:5’-CTTTTCCCCAAATGATCACTCTCACCCTGGGTCAGGAAAA-3’ 
  
     
  
VI. FW:5’-TGTGTCCTTCAGAGTGATCACTAagctTCGAATCGCGAATTCG-3’ 
  RV:5’-CGATTCGAagctTAGTGATCACTCTGAAGGACACACACCCTGGGTC-3’ 
                                 Table III.1: Sequences of the primers used for the 5’ RACE 
 
 
RT-PCR for human TNW       Size bp 
I. FW: 5’- AAGCCAGGAGAGGCATACAAGG-3’ 149 bp 




     
  
II. FW:5’- AATGCCCTCACAGAAATTGACAG-3’ 265 bp 
  RV:5’- GTGTCAGCCTTCTTGCTCTC-3’     
                                                    Table III.2: Sequences of the primers used for the RT-PCR 
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  -SMA -Smooth muscle actin 
 
PH Partial hepatectomy 
 BMP Bone morphogenetic proteins  
 
Prrx1 Paired-related homeobox 1 
 BMSCs  Bone marrow derived stem cells  PSE Proximal sequence element  
 CAFs Cancer associated fibroblasts 
 
RACE Rapid amplification of cDNA ends 
DCC Dextran-coated charcoal  
 
RGD Arg-Gly-Asp 
  E-box Enhancer box sequence 
 
ROS Reactive oxygen species  
 EMT Epithelial-mesenchymal transition SBE Smad-binding element  
 EndMT Endothelial to mesenchymal transition  SLRPs Small leucine-rich repeat proteoglycans 
GAGs Glycosaminoglycans 
 
SRF Serum response factor 
 GCs Glucocorticoids 
  
TGF Transforming growth factor beta  
HA Hyaluronan 
  
TLRs Toll-like receptors  
  HGF Hepatocyte growth factor 
 
TNF- Tumor necrosis factor 
 HIFs Hypoxia-inducible factors 
 
TSS Transcription start site 
 HPSE Heparanase enzyme 
 
VEGF Vascular endothelial growth factor 
HS Heparan sulfate 
       HSCs Hepatic stellate cells 
      ILK Integrin-linked kinase  
      LOX Lysyl oxidase 
       LPS Lipopolysaccharide 
       mef2c Myocyte enhancer factor 2C 
      MET Mesenchymal-epithelial transition 
     MKL1 Megakaryoblastic leukemia-1 
      MMPs Matrix metalloproteases 
      MSCs Mesenchymal stem cells 
      MSl1 Musashi homolog 1 
       NADPH Nicotinamide adenine dinucleotide phosphate-oxidase 
   NFAT5 Nuclear factor of activated T cells 5 
     
  
NGF Nerve growth factor  
      
  
nGRE Negative glucocorticoid response element 
    Nox1 NADPH oxidase 1 
       
  
Otx2 Orthodenticle homolog 2 
      
  
PDGF Platelet-derived growth factor 
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